US20220081439A1 - Haloallylamine compounds and application thereof - Google Patents

Haloallylamine compounds and application thereof Download PDF

Info

Publication number
US20220081439A1
US20220081439A1 US17/421,428 US202017421428A US2022081439A1 US 20220081439 A1 US20220081439 A1 US 20220081439A1 US 202017421428 A US202017421428 A US 202017421428A US 2022081439 A1 US2022081439 A1 US 2022081439A1
Authority
US
United States
Prior art keywords
alkyl
alkoxy
independently selected
optionally substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/421,428
Other languages
English (en)
Inventor
Zhonghui Wan
Lin Li
Frank Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transthera Sciences Nanjing Inc
Original Assignee
Transthera Sciences Nanjing Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transthera Sciences Nanjing Inc filed Critical Transthera Sciences Nanjing Inc
Assigned to TRANSTHERA SCIENCES (NANJING), INC. reassignment TRANSTHERA SCIENCES (NANJING), INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LI, LIN, WU, FRANK, WAN, Zhonghui
Publication of US20220081439A1 publication Critical patent/US20220081439A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • the present invention belongs to the technical field of pharmaceuticals. Specifically, the present invention relates to a halo-allylamine compound or a pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, and the use in preventing and/or treating diseases related to or mediated by the SSAO/VAP-1 protein.
  • SSAO semicarbazide-sensitive amine oxidase
  • VAP-1 vascular adhesion protein-1
  • SSAO structure contains a bivalent copper ion, with a quinonyl group as a coenzyme.
  • SSAO does not have a specific substrate, and its main substrates are aliphatic and aromatic primary amines.
  • WO 2013163675A1 discloses a 3-halo-allylamine derivative as an SSAO/VAP-1 inhibitor (shown as formula I) having inhibitory activity on SSAO/VAP-1 enzyme, and specifically discloses a compound 23, also referred to as PXS-4728, the structure of which is as follows:
  • the SSAO/VAP-1 inhibitor of the present invention can be used to effectively relieve symptoms and lesions under imbalance condition of a variety of disease conditions that is related to SSAO/VAP-1 overexpression etc., thus having a great application prospect.
  • the inventor conducted an in-depth study, and, as a result, developed a novel halo-allylamine compound (hereinafter, sometimes also referred to as “the compound of the present invention”) or a pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof as an SSAO/VAP-1 inhibitor.
  • the compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof as an SSAO/VAP-1 inhibitor.
  • Such an inhibitor compound exhibits excellent inhibitory activity on the SSAO/VAP-1 protein, so it can be used to prevent and/or treat diseases related to or mediated by the SSAO/VAP-1 protein.
  • the SSAO/VAP-1 inhibitor compound of the present invention shows excellent inhibition on SSAO/VAP-1 protein and shows excellent selectivity against rhAOC1 protein and MAO protein, thus preventing other unnecessary side effects while preventing and/or treating diseases related to or mediated by the SSAO/VAP-1 protein.
  • the SSAO/VAP-1 inhibitor compound of the present invention can hardly penetrate the blood-brain barrier, so the compound of the present invention has a very low toxic risk to the nervous system, showing excellent drug safety.
  • the present invention provides the following technical solutions.
  • R 1 and R 2 are each independently selected from hydrogen and halogen, and R 1 and R 2 are not both hydrogen;
  • R 3 and R 4 are each independently selected from hydrogen and C 1-6 alkyl optionally substituted by a substituent A, or form a 5-10 membered nitrogen containing heterocyclyl optionally substituted by a substituent A along with an N atom connected thereto;
  • R 5 and R 6 are each independently selected from hydrogen and C 1-6 alkyl optionally substituted by a substituent A;
  • L 1 is a bond or —CR′R′′—, —NR′—, —S—, —SO 2 —, —S(O)—, —SONR′—, —SO 2 NR′— or —NR′CONR′—, and R′ and R′′ are each independently selected from hydrogen and C 1-6 alkyl optionally substituted by a substituent A;
  • Cy 1 is a group shown as general formula (A), (a), (b) or (c) below that is unsubstituted or substituted by one or more R a :
  • n is an integer from 0 to 2;
  • Y 1 , Y 2 , Y 3 and Y 4 are each independently selected from CR c R c , NR d , O and S;
  • X 1 , X 2 , X 3 , X 4 , X 9 and X 10 are each independently selected from CR c R c , NR d , O and S, X 5 , X 6 , X 7 and X 8 are each independently selected from CR c R c and NR d , and at least one of X 1 , X 2 and X 3 is NR d ;
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarboxyl, C 1-6 alkyl optionally substituted by one or more R b , C 2-6 alkenyl optionally substituted by one or more R b , C 2-6 alkynyl optionally substituted by one or more R b , C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkylthio optionally substituted by one or more R b , C 1-6 alkylthio C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkylamino optionally substituted by one or more R
  • Cy 2 is each independently selected from 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocyclyl, 6-10 membered aryl and 5-14 membered heteroaryl;
  • each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, amino C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, amino C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylthio, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylaminocarbonyl, (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylcarbonyl, C 1-6 alkylaminosulfonyl, (C 1-6 alkyl) 2 aminosulfonyl, C 1-6 alkylsulfonylamino and C 1-6 al
  • the substituents A are each independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, amino C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, amino C 1-6 alkoxy, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylaminocarbonyl, (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylcarbonyl, C 1-6 alkylsulfonylamino, C 1-6 alkylaminosulfonyl, (C 1-6 alkyl) 2 aminosulfonyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1-6 alkylsulfony
  • R c is absent, or is each independently selected from hydrogen atom when present; or two R c form an oxo group together;
  • R d is absent, or is each independently selected from hydrogen atom when present;
  • Solution 2 The compound or the pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof according to solution 1,
  • R 1 and R 2 are each independently selected from hydrogen and halogen, and R 1 and R 2 are not both hydrogen;
  • R 3 and R 4 are each independently selected from hydrogen and C 1-6 alkyl
  • R 5 and R 6 are each independently selected from hydrogen and C 1-6 alkyl
  • L 1 is a bond or —CR′R′′—, —NR′— or —S—, and R′ and R′′ are each independently selected from hydrogen and C 1-6 alkyl;
  • n is an integer from 0 to 2;
  • Y 1 , Y 2 , Y 3 and Y 4 are each independently selected from CR c R c and NR d ;
  • X 1 , X 2 , X 3 , X 4 , X 9 and X 10 are each independently selected from CR c R c and NR d , and at least one of X 1 , X 2 and X 3 is NR d ;
  • X 5 , X 6 , X 7 and X 8 are each independently selected from CR c R c and NR d ;
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkylthio optionally substituted by one or more R b , C 1-6 alkylthio C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkylamino optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino optionally substituted by one or more R b , C 1-6 alkylamino C 1-6 alkyl optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino optionally substitute
  • Cy 2 is each independently selected from 3-8 membered cycloalkyl, 5-10 membered heterocyclyl, phenyl, naphthyl and 5-10 membered heteroaryl;
  • each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl, C 1-6 alkoxy, amino C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, amino C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylthio, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylaminocarbonyl, (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkylcarbonylamino and C 1-6 alkylcarbonyl;
  • the substituents A are each independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1-6 alkyl, C 1-6 alkoxy, amino C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, amino C 1-6 alkoxy, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylaminocarbonyl, (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylcarbonyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1-6 alkylthio, 3-8 membered cycloalkyl, 5-10 membered heterocyclyl, phenyl, naphthyl, 5-10 membered heteroaryl and oxo;
  • each R a is independently selected from hydroxyl, amino, cyano, halogen, aminocarbonyl, C 1-4 alkyl optionally substituted by one or more R b , C 1-4 alkoxy optionally substituted by one or more R b , C 1-4 alkoxy C 1-4 alkyl optionally substituted by one or more R b , C 1-4 alkoxy C 1-4 alkoxy optionally substituted by one or more R b , C 1-4 alkylthio optionally substituted by one or more R b , C 1-4 alkylthio C 1-4 alkyl optionally substituted by one or more R b , C 1-4 alkylamino optionally substituted by one or more R b , (C 1-4 alkyl) 2 amino optionally substituted by one or more R b , C 1-4 alkylamino C 1-4 alkyl optionally substituted by one or more R b , (C 1-4 alkyl) 2 amino optionally substituted by one or more R
  • each R b is independently selected from hydroxyl, amino, cyano, halogen, aminocarbonyl, C 1-4 alkyl, C 1-4 alkoxy, amino C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy C 1-4 alkyl, C 1-4 alkoxy C 1-4 alkoxy, amino C 1-4 alkoxy, C 1-4 haloalkoxy, C 1-4 alkylthio, C 1-4 alkylamino, (C 1-4 alkyl) 2 amino, C 1-4 alkylaminocarbonyl, (C 1-4 alkyl) 2 aminocarbonyl, C 1-4 alkylcarbonylamino and C 1-4 alkylcarbonyl;
  • the substituents A are each independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1-4 alkyl, C 1-4 alkoxy, amino C 1-4 alkyl, C 1-4 alkoxy C 1-4 alkyl, C 1-4 alkoxy C 1-4 alkoxy, amino C 1-4 alkoxy, C 1-4 alkylamino, (C 1-4 alkyl) 2 amino, C 1-4 alkylaminocarbonyl, (C 1-4 alkyl) 2 aminocarbonyl, C 1-4 alkylcarbonylamino, C 1-4 alkylcarbonyl, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 1-4 alkylthio, 3-6 membered cycloalkyl, 5-10 membered heterocyclyl, phenyl, naphthyl, 5-10 membered heteroaryl and oxo;
  • At least one of Y 1 , Y 2 , Y 3 and Y 4 is C ⁇ O;
  • R a when R a is present, at least one R a is connected to any one of Y 1 , Y 2 , Y 3 and Y 4 ;
  • R a when R a is present, at least one R a is connected to any one of Y 1 , Y 2 and Y 3 ;
  • At least one R a is present, and at least one R a is connected to any one of X 5 , X 6 , X 7 and X 8 ;
  • the L 1 group is connected to X 1 , X 2 or X 3 in formula (A);
  • the L 1 group is connected to X 1 , X 2 or X 3 in formula (A);
  • the L 1 group is connected to X 1 , X 2 , X 3 or X 4 in formula (c);
  • the L 1 group is connected to an N atom.
  • Solution 3 The compound or the pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof according to solution 1 or solution 2:
  • Cy 1 is a group shown as general formula (A-1), (A-2), (A-3), (a), (b) or (c) below that is unsubstituted or substituted by one or more R a :
  • Solution 4 The compound or the pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof according to any one of solutions 1-3,
  • Cy 1 is a group shown as general formula (A-11), (a-1), (a-2), (b-1), (c-1) or (c-2) below that is unsubstituted or substituted by one or more R a :
  • n is an integer that is 1 or 2;
  • Y 1 , Y 2 and Y 3 are each independently selected from CH 2 , NH, CH and N;
  • X 1 , X 2 , X 3 , X 4 and X 9 are each independently selected from CH 2 , CH, N, NH and C ⁇ O, and at least one of X 1 , X 2 and X 3 is N or NH;
  • R a when R a is present, at least one R a is connected to Y 2 ;
  • R a when R a is present, at least one R a is connected to Y 2 ;
  • R a when R a is present, at least one R a is connected to Y 1 ;
  • R a when R a is present, at least one R a is connected to a cyclic carbon atom;
  • At least one R a is present, and at least one R a is connected to a benzene ring group.
  • Solution 5 The compound or the pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof according to any one of solutions 1-4,
  • Cy 1 is a group shown as general formula (A-11) or (a-1) below that is unsubstituted or substituted by one or more R a :
  • n is an integer that is 1 or 2;
  • Y 2 and Y 3 are each independently selected from CH 2 , NH, CH and N;
  • X 1 , X 2 and X 3 are each independently selected from CH 2 , CH, N, NH and C ⁇ O, and at least one of X 1 , X 2 and X 3 is N or NH;
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkylamino optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino optionally substituted by one or more R b , C 1-6 alkylamino C 1-6 alkyl optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkylaminocarbonyl optionally substituted by one or more R b , (C 1-6 alkyl)
  • Cy 2 is each independently selected from 3-8 membered cycloalkyl, 5-10 membered heterocyclyl, phenyl, naphthyl and 5-10 membered heteroaryl; each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl, C 1-6 alkoxy, amino C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, amino C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylthio, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylaminocarbonyl, (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkylcarbonylamino and C 1-6 alkylcarbonyl;
  • Cy 2 is each independently selected from 3-6 membered cycloalkyl, 5-6 membered heterocyclyl, phenyl, naphthyl and 5-6 membered heteroaryl;
  • R a is each independently selected from halogen, cyano, C 1-6 alkyl optionally substituted by at least one of halogen, C 1-6 alkyl, C 1-6 alkoxy and 3-6 membered cycloalkyl, 3-8 membered cycloalkyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, phenyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, and 5-6 membered heteroaryl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy;
  • R a is each independently selected from halogen, cyano, C 1-4 alkyl optionally substituted by at least one of halogen, C 1-6 alkyl, C 1-6 alkoxy and 3-5 membered cycloalkyl, 3-5 membered cycloalkyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, phenyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, and 5-6 membered nitrogen heteroaryl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy;
  • X 1 and X 2 are each independently selected from CH 2 , CH, N and NH;
  • X 1 and X 2 are each independently selected from CH 2 , CH, N and NH;
  • Y 2 is NH
  • Y 3 is CH 2 or CH;
  • the L 1 group is connected to X 1 , X 2 or X 3 ;
  • the L 1 group is connected to an N atom.
  • Solution 6 The compound or the pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof according to solution 5,
  • R 1 and R 2 are each independently selected from hydrogen and halogen, and R 1 and R 2 are not both hydrogen;
  • R 3 and R 4 are each independently selected from hydrogen and C 1-6 alkyl
  • R 5 and R 6 are each independently selected from hydrogen and C 1-6 alkyl
  • L 1 is a bond
  • Cy 1 is one of the following groups unsubstituted or substituted by one or more R a :
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkylamino optionally substituted by one or more R b , C 1-6 alkylamino C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkylaminocarbonyl optionally substituted by one or more R b , C 1-6 alkylaminocarbonyl C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkylaminocarbonyl C 1-6 alkyl optionally substituted by one or more R b ,
  • Cy 2 is each independently selected from 3-8 membered cycloalkyl, 5-10 membered heterocyclyl, phenyl, naphthyl and 5-10 membered heteroaryl; each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl, C 1-6 alkoxy, amino C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, amino C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylthio, C 1-6 alkylamino, C 1-6 alkylaminocarbonyl, C 1-6 alkylcarbonylamino and C 1-6 alkylcarbonyl;
  • Cy 2 is each independently selected from 3-6 membered cycloalkyl, 5-6 membered heterocyclyl, phenyl and 5-6 membered heteroaryl;
  • R a is each independently selected from halogen, cyano, C 1-6 alkyl optionally substituted by at least one of halogen, C 1-6 alkyl, C 1-6 alkoxy and 3-6 membered cycloalkyl, 3-8 membered cycloalkyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, phenyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, and 5-6 membered heteroaryl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy.
  • R a is each independently selected from fluorine; chlorine; bromine; cyano; methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl optionally substituted by at least one of halogen, C 1-6 alkyl, C 1-6 alkoxy and 3-5 membered cycloalkyl; cyclopropyl, cyclobutyl and cyclopentyl optionally substituted by at least one of halogen and C 1-6 alkyl; phenyl optionally substituted by at least one of halogen and C 1-6 alkyl; and pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl optionally substituted by at least one of halogen and C 1-6 alkyl.
  • Solution 7 The compound or the pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof according to any one of solutions 1-4,
  • Cy 1 is a group shown as general formula (b-1) below that is unsubstituted or substituted by one or more R a :
  • X 1 , X 2 , X 3 and X 9 are each independently selected from CH 2 , CH, N and NH, and at least one of X 1 , X 2 and X 3 is N or NH;
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkylamino optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino optionally substituted by one or more R b , C 1-6 alkylamino C 1-6 alkyl optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkylaminocarbonyl optionally substituted by one or more R b , (C 1-6 alkyl)
  • Cy 2 is each independently selected from 3-8 membered cycloalkyl, 5-10 membered heterocyclyl, phenyl, naphthyl and 5-10 membered heteroaryl;
  • each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl, C 1-6 alkoxy, amino C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, amino C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylthio, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylaminocarbonyl, (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkylcarbonylamino and C 1-6 alkylcarbonyl;
  • Cy 2 is each independently selected from 3-6 membered cycloalkyl, 5-6 membered heterocyclyl, phenyl and 5-6 membered heteroaryl;
  • R a is each independently selected from C 1-6 alkyl optionally substituted by halogen; halogen; aminocarbonyl; C 1-6 alkylaminocarbonyl optionally substituted by halogen; (C 1-6 alkyl) 2 aminocarbonyl optionally substituted by halogen; 3-8 membered cycloalkylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy; phenylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy; 5-6 membered heteroarylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy; and 5-10 membered heterocyclylcarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy;
  • R a is each independently selected from aminocarbonyl, C 1-4 alkylaminocarbonyl optionally substituted by halogen, (C 1-4 alkyl) 2 aminocarbonyl optionally substituted by halogen, 3-5 membered cycloalkylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, phenylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy and 5-6 membered nitrogen containing heterocyclylcarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy.
  • the L 1 group is connected to the N atom in formula (b-1);
  • Solution 8 The compound or the pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof according to solution 7,
  • R 1 and R 2 are each independently selected from hydrogen and halogen, and R 1 and R 2 are not both hydrogen;
  • R 3 and R 4 are each independently selected from hydrogen and C 1-6 alkyl
  • R 5 and R 6 are each independently selected from hydrogen and C 1-6 alkyl
  • L 1 is a bond
  • Cy 1 is one of the following groups unsubstituted or substituted by one or more R a :
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkylamino optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino optionally substituted by one or more R b , C 1-6 alkylamino C 1-6 alkyl optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkylaminocarbonyl optionally substituted by one or more R b , (C 1-6 alkyl)
  • Cy 2 is each independently selected from 3-8 membered cycloalkyl, 5-10 membered heterocyclyl, phenyl and 5-10 membered heteroaryl;
  • each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl, C 1-6 alkoxy, amino C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, amino C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylthio, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylaminocarbonyl, (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkylcarbonylamino and C 1-6 alkylcarbonyl;
  • Cy 2 is each independently selected from 3-6 membered cycloalkyl, 5-6 membered heterocyclyl, phenyl and 5-6 membered heteroaryl;
  • R a is each independently selected from C 1-6 alkyl optionally substituted by halogen; halogen; aminocarbonyl; C 1-6 alkylaminocarbonyl optionally substituted by halogen; (C 1-6 alkyl) 2 aminocarbonyl optionally substituted by halogen; 3-8 membered cycloalkylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy; phenylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy; 5-6 membered heteroarylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy; and 5-10 membered heterocyclylcarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy;
  • R a is each independently selected from aminocarbonyl, methylaminocarbonyl optionally substituted by halogen, ethylaminocarbonyl optionally substituted by halogen, propylaminocarbonyl optionally substituted by halogen, isopropylaminocarbonyl optionally substituted by halogen, n-aminocarbonyl optionally substituted by halogen, isobutylaminocarbonyl optionally substituted by halogen, sec-butylaminocarbonyl optionally substituted by halogen, tert-butylaminocarbonyl optionally substituted by halogen, cyclopropylaminocarbonyl optionally substituted by at least one of halogen and C 1-6 alkyl, cyclobutylaminocarbonyl optionally substituted by at least one of halogen and C 1-6 alkyl, cyclopentylaminocarbonyl optionally substituted by at least one of halogen and C 1-6
  • Solution 9 The compound or the pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof according to any one of solutions 1-4,
  • Cy 1 is a group shown as general formula (c-1) below that is substituted by one or more R a :
  • X 1 , X 2 and X 3 are each independently selected from CH 2 , CH, N, NH and C ⁇ O, and at least one of X 1 , X 2 and X 3 is N or NH;
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkylamino optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino optionally substituted by one or more R b , C 1-6 alkylamino C 1-6 alkyl optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkylaminocarbonyl optionally substituted by one or more R b , (C 1-6 alkyl)
  • Cy 2 is each independently selected from 3-8 membered cycloalkyl, 5-10 membered heterocyclyl, phenyl, naphthyl and 5-10 membered heteroaryl;
  • each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl, C 1-6 alkoxy, amino C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, amino C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylthio, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylaminocarbonyl, (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkylcarbonylamino and C 1-6 alkylcarbonyl;
  • Cy 2 is each independently selected from 3-6 membered cycloalkyl, 5-6 membered heterocyclyl, phenyl and 5-6 membered heteroaryl; preferably, R a is each independently selected from C 1-6 alkyl optionally substituted by halogen; halogen; aminocarbonyl; C 1-6 alkylaminocarbonyl optionally substituted by halogen; (C 1-6 alkyl) 2 aminocarbonyl optionally substituted by halogen; 3-8 membered cycloalkylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy; phenylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy; 5-6 membered heteroarylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy; and 5-10 membered heterocyclylcarbonyl
  • R a is each independently selected from aminocarbonyl, C 1-4 alkylaminocarbonyl optionally substituted by halogen, (C 1-4 alkyl) 2 aminocarbonyl optionally substituted by halogen, 3-5 membered cycloalkylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, phenylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy and 5-6 membered nitrogen containing heterocyclylcarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy;
  • At least one R a is connected to the benzene ring moiety in formula (c-1);
  • the L 1 group is connected to X 1 , X 2 or X 3 ; preferably, in formula (c-1), the L 1 group is connected to the N atom in formula (c-1).
  • Solution 10 The compound or the pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof according to solution 9,
  • R 1 and R 2 are each independently selected from hydrogen and halogen, and R 1 and R 2 are not both hydrogen;
  • R 3 and R 4 are each independently selected from hydrogen and C 1-6 alkyl
  • R 5 and R 0 are each selected from hydrogen and C 1-6 alkyl
  • L 1 is a bond
  • Cy 1 is the following group substituted by one or more substituent R a :
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkylamino optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino optionally substituted by one or more R b , C 1-6 alkylamino C 1-6 alkyl optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkylaminocarbonyl optionally substituted by one or more R b , (C 1-6 alkyl)
  • Cy 2 is each independently selected from 3-8 membered cycloalkyl, 5-10 membered heterocyclyl, phenyl and 5-10 membered heteroaryl;
  • each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl, C 1-6 alkoxy, amino C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, amino C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylthio, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylaminocarbonyl, (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkylcarbonylamino and C 1-6 alkylcarbonyl;
  • Cy 2 is each independently selected from 3-6 membered cycloalkyl, 5-6 membered heterocyclyl, phenyl and 5-6 membered heteroaryl;
  • R a is each independently selected from C 1-6 alkyl optionally substituted by halogen; halogen; aminocarbonyl; C 1-6 alkylaminocarbonyl optionally substituted by halogen; (C 1-6 alkyl) 2 aminocarbonyl optionally substituted by halogen; 3-8 membered cycloalkylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy; phenylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy; 5-6 membered heteroarylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy; and 5-10 membered heterocyclylcarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy;
  • R a is each independently selected from aminocarbonyl, methylaminocarbonyl optionally substituted by halogen, ethylaminocarbonyl optionally substituted by halogen, propylaminocarbonyl optionally substituted by halogen, isopropylaminocarbonyl optionally substituted by halogen, n-aminocarbonyl optionally substituted by halogen, isobutylaminocarbonyl optionally substituted by halogen, sec-butylaminocarbonyl optionally substituted by halogen, tert-butylaminocarbonyl optionally substituted by halogen, cyclopropylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, cyclobutylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, cyclopentylaminocarbonyl optionally substituted by
  • Solution 11 The compound or the pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof according to solution 1.
  • the compound is selected from:
  • Solution 12 A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof according to any one of solutions 1-11, wherein the pharmaceutical composition optionally comprises one or more pharmaceutically acceptable carriers.
  • Solution 13 Use of the compound or the pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof according to any one of solutions 1-11 or the pharmaceutical composition according to solution 12 in the manufacture of a medicament for preventing and/or treating diseases related to or mediated by the SSAO/VAP-1 protein.
  • the present invention provides a novel halo-allylamine compound, which is effective in preventing and/or treating diseases related to or mediated by the SSAO/VAP-1 protein.
  • the compound shown as formula I and the pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof of the present invention exhibits excellent inhibitory activity against the SSAO/VAP-1 protein, and thus can be used to prevent and/or treat diseases related to or mediated by the SSAO/VAP-1 protein.
  • the compound of the present invention shows excellent inhibition on the SSAO/VAP-1 protein and shows excellent selectivity against the rhAOC1 protein and the MAO protein. Therefore, the compound of the present invention avoids other undesired side effects while preventing and/or treating diseases related to or mediated by the SSAO/VAP-1 protein.
  • the compound of the present invention can hardly penetrate the blood-brain barrier. Therefore, the compound of the present invention has a very low toxic risk to the nervous system, showing excellent drug safety.
  • the present invention can provide a highly safe compound or a pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof that can prevent and/or treat diseases related to or mediated by the SSAO/VAP-1 protein.
  • C a-b group (a and b represent an integer ⁇ 1, and a ⁇ b) means that the “group” has a to b carbon atoms, for example, C 1-6 alkyl represents alkyl with 1-6 carbon atoms, C 1-6 alkoxy represents alkoxy with 1-6 carbon atoms, C 3-8 cycloalkyl represents cycloalkyl with 3-8 carbon atoms, and C 1-6 alkoxy C 1-6 alkyl represents a group formed by bonding alkoxy having 1-6 carbon atoms with alkyl having 1-6 carbon atoms.
  • the expression of “group” may also refer to a group containing two or more subgroups, and at this point, the expression of “C a -b” defines the number of carbon atoms of the entire group containing the two or more subgroups.
  • the expression of “C 7-12 alkylaryl” means that the total number of carbon atoms of an alkylaryl group comprising an alkyl moiety and an aryl moiety is 7-10, that is, it can be decomposed into, but is not limited to, C 1-6 alkylphenyl or C 1-2 alkylnaphthyl.
  • group represents a monovalent group or a divalent or higher group meeting the valence as required.
  • cycloalkyl (also expressed as cycloalkyl group) includes a monovalent group obtained by removing a hydrogen atom from cycloalkane, as well as a divalent or higher group obtained by removing two or more hydrogen atoms from the same carbon atom or two or more different carbon atoms of cycloalkane.
  • cycloalkyl when “cycloalkyl” serves as a terminal group, it is connected to other parts of the compound structure in the form of a monovalent group when not carrying substituents; and when it carries substituents, cycloalkyl shows a corresponding valence number (substituent number+1) according to the number of the substituents carried.
  • a “group” represents a divalent or higher group, it is preferred to connect these bonds to different atoms (such as but not limited to carbon atoms, nitrogen atoms, etc.) in the group.
  • Halogen or “halogen atom” described in the present invention refers to fluorine, chlorine, bromine, and iodine, preferably fluorine and chlorine.
  • C 1-6 alkyl described in the present invention refers to a linear or branched alkyl group derived by removing a hydrogen atom from an alkane moiety containing 1 to 6 carbon atoms, and includes linear C 1-6 alkyl and branched C 1-6 alkyl. In fact, it is well-known by those skilled in the art that C 1-6 alkyl has at least three carbon atoms when having a branch chain (branched C 1-6 alkyl).
  • C 1-6 alkyl may include, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, ten-butyl, n-pentyl, isopentyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, n-hexyl, isohexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, 1-methyl-2-methylpropyl, etc.
  • the “C 1-4 alkyl” refers to the aforementioned examples containing 1 to 4 carbon atoms.
  • C 2-6 alkenyl refers to a linear or branched alkenyl group derived by removing a hydrogen atom from alkene that contains 2 to 6 carbon atoms and at least one carbon-carbon double bond, for example, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1,3-butadiene-1-yl, 1-pentene-3-yl, 2-pentene-1-yl, 3-pentene-1-yl, 3-pentene-2-yl, 1,3-pentadiene-1-yl, 1,4-pentadiene-3-yl, 1-hexene-3-yl, 1,4-hexadiene-1-yl, etc.
  • “C 2-6 alkenyl” contains a carbon-carbon double bond.
  • C 2-6 alkynyl refers to a linear or branched alkynyl group derived by removing a hydrogen atom from alkyne that contains 2 to 6 carbon atoms and at least one carbon-carbon triple bond, for example, ethynyl, propynyl, 2-butyn-1-yl, 2-pentyn-1-yl, 3-pentyn-1-yl, 4-methyl-2-pentyn-1-yl, 2-hexyn-1-yl, 3-hexyn-2-yl, 3-hexyn-1-yl, 3-hexyn-2-yl, etc.
  • “C 2-6 alkynyl” contains a carbon-carbon triple bond.
  • C 1-6 alkoxy described in the present invention refers to a group derived by connecting “C 1-6 alkyl” defined above to other parts of the chemical structural formula through oxygen atoms, i.e. a “C 1-6 alkyl-O—” group, such as groups obtained by bonding the groups enumerated regarding the aforementioned “C 1-6 alkyl” to —O—, including, but not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, tert-butoxy, n-pentyloxy, neopentyloxy, n-hexyloxy, etc.
  • the “C 1-4 alkoxy” refers to the aforementioned examples containing 1 to 4 carbon atoms, i.e. a “C 1-4 alkyl-O—” group.
  • C 1-6 alkoxy C 1-6 alkoxy refers to a group formed by substituting one or more hydrogen atoms on C 1-6 alkoxy with C 1-6 alkoxy.
  • C 1-6 alkylamino (C 1-6 alkylamino) “(C 1-6 alkyl) 2 amino”, “C 1-6 alkylcarbonylamino”, “C 1-6 alkylaminocarbonyl”, “C 1-6 alkylcarbonyl”, “C 1-6 alkylaminosulfonyl”, “C 1-6 alkylsulfonylamino”, “C 1-6 alkylsulfonyl”, “C 1-6 alkylthio (C 1-6 alkylthio)”, etc., described in the present invention refer to groups formed by respectively connecting C 1-6 alkyl to corresponding groups such as —NH 2 , —CO—NH 2 —, —NH 2 —CO—, —CO—, —NH 2 SO 2 —, —SO 2 NH 2 —, —SO 2 —, and —S—.
  • the “polycyclic ring” in the present invention refers to a multi-ring system structure formed by two or more ring structures connected by an ortho-fused, spiro- or bridged linkage.
  • the ortho-fused ring refers to a polycyclic structure formed by two or more ring structures sharing two adjacent ring atoms (i.e., sharing a bond) with each other.
  • the bridged ring refers to a polycyclic structure formed by two or more ring structures sharing two non-adjacent ring atoms with each other.
  • the spiro-ring refers to a polycyclic structure formed by two or more ring structures sharing a ring atom with each other.
  • cycloalkyl refers to a monovalent group or a bivalent group (as required) derived from cycloalkane, and the cycloalkane includes monocyclic cycloalkane or polycyclic cycloalkane, and may have 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. Unless otherwise specified, a certain membered cycloalkyl includes all possibly formed monocyclic and polycyclic (including fused in the form of ortho-, spiro- or bridged) cases.
  • Cycloalkyl may be a 3-12 membered monovalent, divalent or higher (as required) group, a 3-10 membered monovalent, divalent or higher (as required) group, a 3-8 membered monovalent, divalent or higher (as required) group, a 3-6 membered monovalent, divalent or higher (as required) group, a 4-6 membered monovalent, divalent or higher (as required) group, or a 5-7 membered monovalent, divalent or higher (as required) group.
  • (Monovalent, divalent or higher) monocyclic cycloalkyl may be 3-12 membered cycloalkyl, 3-10 membered cycloalkyl, 3-8 membered cycloalkyl, 3-6 membered cycloalkyl, 4-6 membered cycloalkyl or 5-7 membered cycloalkyl, examples of which include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentyl-1,3-diyl, cyclohexyl-1,4-diyl, cycloheptyl-1,4-diyl, etc.
  • (Monovalent, divalent or higher) polycyclic cycloalkyl includes ortho-fused cycloalkyl, bridged cycloalkyl and spiro-cycloalkyl.
  • (Monovalent, divalent or higher) ortho-fused cycloalkyl may be 6-12 membered ortho-fused cycloalkyl or 7-10 membered ortho-fused cycloalkyl, examples of which include, but are not limited to, bicyclo[3.1.1]heptyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octanyl, bicyclo[3.2.2]nonyl, bicyclo[3.3.1]nonyl and bicyclo[4.2.1]nonyl.
  • “Cycloalkenyl” described in the present invention refers to a group obtained by having at least one carbon-carbon double bond (preferably having a carbon-carbon double bond) in the aforementioned cycloalkyl group.
  • Cycloalkyl and “cycloalkenyl” may also be monovalent groups obtained by removing a hydrogen atom from 6-12 membered spiro-ring or 7-11 membered spiro-ring or divalent groups (as required) obtained by removing a hydrogen atom each from two different carbon atoms.
  • Examples of spiro-ring include but are not limited to:
  • “Cycloalkyl” and “cycloalkenyl” may also be monovalent groups obtained by removing a hydrogen atom from 6-12 membered bridged ring or 7-11 membered bridged ring or divalent groups (as required) obtained by removing a hydrogen atom each from two different carbon atoms.
  • Examples of the bridge ring include but are not limited to:
  • 3-12 membered cycloalkenyl described in the present invention includes all possibly formed monocyclic and polycyclic (including fused in the form of ortho-, spiro- or bridged) cases. It is a group that has at least one carbon-carbon double bond in the 3-12 membered monovalent, divalent or higher (as required) cycloalkyl group enumerated above. For example, it may be a monovalent or bivalent group derived from 3-8 membered cycloalkenyl, 7-11 membered spiro-cycloalkenyl, 7-11 membered ortho-fused cycloalkenyl, 6-11 membered bridged cycloalkenyl or the like.
  • Examples include cyclobutenyl, cyclopentenyl, cyclohexenyl, 1,4-cyclohexadienyl, cycloheptenyl, 1,4-cycloheptadienyl, cyclooctenyl and 1,5-cyclooctadienyl.
  • Heterocyclyl described in the present invention refers to a nonaromatic monovalent or bivalent cyclic group formed by substituting at least one cyclic carbon atom of the aforementioned cycloalkyl with a heteroatom selected from O, S and N, preferably not having or having a carbon-carbon double bond.
  • it is a heterocyclyl obtained by substituting the ring-forming carbon atoms of the aforementioned ring-forming alkyl with 1 to 3 heteroatoms selected from O, S and N.
  • heterocyclyl described in the present invention further includes the case of the carbon atoms or sulfur atoms as ring-forming atoms being substituted by oxygen or nitrogen, for example, the ring-forming carbon atoms are substituted by C( ⁇ O), S( ⁇ O), S( ⁇ O) 2 and S( ⁇ O)( ⁇ NH).
  • the “heterocyclyl” of the present invention may be a group with 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 ring-forming atoms. It may be 3-14 membered heterocyclyl, 3-12 membered heterocyclyl, 3-10 membered heterocyclyl, 4-10 membered heterocyclyl, 3-8 membered heterocyclyl, 4-12 membered heterocyclyl, 4-8 membered heterocyclyl, 4-6 membered heterocyclyl or 5-10 membered heterocyclyl.
  • heterocyclyl further includes a monovalent, bivalent or higher (as required) monocyclic heterocyclyl system or a monovalent, bivalent or higher (as required) polycyclic heterocyclyl system (also referred to as a polycyclic system), and includes a saturated or unsaturated heterocyclyl group, and it is not aromatic as a whole. Unless otherwise specified, it includes all possibly formed monocyclic, polycyclic (including fused in the form of ortho-, spiro- or bridged), saturated and unsaturated cases, and it is not aromatic as a whole.
  • Monovalent, bivalent or higher (as required) monocyclic heterocyclyl may be 3-14 membered heterocyclyl, 3-12 membered heterocyclyl, 3-10 membered heterocyclyl, 4-10 membered heterocyclyl, 3-8 membered heterocyclyl, 4-12 membered heterocyclyl, 4-8 membered heterocyclyl, 4-6 membered heterocyclyl, 5-10 membered heterocyclyl, 3-8 membered saturated heterocyclyl, 3-6 membered heterocyclyl, 4-12 membered heterocyclyl, 4-7 membered heterocyclyl, 4-6 membered heterocyclyl, 5-10 membered heterocyclyl, 5-7 membered heterocyclyl, 5-6 membered heterocyclyl, 5-6 membered oxygen containing heterocyclyl, 5-6 membered nitrogen containing heterocyclyl, 5-6 membered saturated heterocyclyl, 5-7 membered saturated heterocyclyl or the like, which may be saturated, partially saturated or unsaturated
  • azacyclopropyl 2H-azacyclopropyl, diazacyclopropyl, 3H-diazacyclopropyl, azetidinyl, 1,4-dioxacyclohexyl, 1,3-dioxacyclohexyl, 1,3-dioxacyclopentyl, 1,4-dioxacyclohexadienyl, tetrahydrofuryl, dihydropyrrolyl, pyrrolidinyl, imidazolidinyl, 4,5-dihydroimidazolyl, pyrazolidinyl, 4,5-dihydropyrazolyl, 2,5-dihydrothienyl, tetrahydrothienyl, 4,5-dihydrothiazolyl, piperidyl, piperazinyl, morpholinyl, hexahydropyrimidinyl, hexahydro
  • the monovalent, divalent or higher (as required) polycyclic heterocyclyl includes ortho-fused heterocyclyl, spiro-heterocyclyl and bridged heterocyclyl, which may be saturated, partially saturated or unsaturated, but nonaromatic.
  • the ortho-fused heterocyclyl may be a 6-12 membered ortho-fused heterocyclyl, 7-10 membered ortho-fused heterocyclyl, 6-10 membered ortho-fused cyclyl, 6-12 membered saturated ortho-fused heterocyclyl, 7-8 membered saturated ortho-fused heterocyclyl or 8 membered saturated ortho-fused heterocyclyl, and its examples include, but are not limited to: 3-azabicyclo[3.1.0]hexyl, 3,6-diazabicyclo[3.2.0]heptyl, 3,8-diazabicyclo[4.2.0]octyl, 3,7-diazabicyclo[4.2.0]octyl, octahydropyrrolo[3,4-c]pyrrolyl, octahydropyrrolo [3,4-&]pyrrolyl, octahydropyrrolo[3,4-b][1,4]oxazinyl, octa
  • the spiro-heterocyclyl may be a monovalent group obtained by removing a hydrogen atom from 6-12 membered spiro heterocyclic ring, 7-11 membered spiro heterocyclic ring, 6-12 membered saturated spiro heterocyclic ring or 7 membered saturated spiro heterocyclic ring, or a bivalent group (as required) obtained by removing a hydrogen atom each from two different carbon atoms, and the examples of the spiro heterocyclyl include but are not limited to:
  • the bridged heterocyclyl may be a monovalent group obtained by removing a hydrogen atom from 6-12 membered bridged heterocyclic ring, 7-11 membered bridged heterocyclic ring, 6-12 membered saturated bridged heterocyclic ring or 7-8 membered saturated bridged heterocyclic ring, or a bivalent group (as required) obtained by removing a hydrogen atom each from two different carbon atoms, and the examples of the bridged heterocyclyl include but are not limited to:
  • Aryl described in the present invention refers to a monovalent group or a bivalent or higher group as required derived from aromatic carbocyclic hydrocarbon, and the aromatic carbocyclic hydrocarbon includes 6-8 membered monocyclic aromatic hydrocarbon and 8-14 membered polycyclic aromatic hydrocarbon.
  • the 6-8 membered monocyclic aryl is, for example, phenyl.
  • the 8-14 membered polycyclic aryl is, for example, naphthyl, phenanthryl, anthryl and the like.
  • Divalent aryl may include, for example, phenylene, naphthylene and the like.
  • Heteroaryl described in the present invention may be 5-14 membered heteroaryl, 5-10 membered heteroaryl or 5-6 membered heteroaryl, and refers to an aromatic monovalent or divalent cyclic group with 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring-forming atoms that has at least one heteroatom selected from O, S and N. Preferably, it has 1 to 3 ring-forming heteroatoms.
  • heteroaryl further includes the case of the carbon atoms or sulfur atoms as ring-forming atoms being substituted by oxygen or nitrogen, such as the case of the carbon atoms being substituted by C( ⁇ O), S( ⁇ O), S( ⁇ O) 2 and S( ⁇ O)( ⁇ NH).
  • heteroaromatic ring described in the present invention may be a monocyclic system or a polycyclic system (fused in the form of ortho-, spiro- or bridged).
  • Heteroaryl includes monocyclic heteroaryl and polycyclic heteroaryl. Unless otherwise specified, a certain membered heteroaryl includes all possibly formed monocyclic, polycyclic, fully aromatic and partially aromatic cases.
  • Monocyclic heteroaryl may be, for example, 5-7 membered heteroaryl or 5-6 membered heteroaryl, examples of which include, but are not limited to, furyl, imidazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxazolyl, isoxazolyl, pyridyl, pyridonyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl and triazinyl.
  • Polycyclic heteroaryl may be 8-12 membered ortho-fused heteroaryl or 9-10 membered ortho-fused heteroaryl, examples of which include, but are not limited to, benzimidazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzothienyl, benzooxadiazolyl, benzothiazolyl, cinnolinyl, indazolyl, indolyl, isoindolyl, isoquinolinyl, naphthyridinyl, purinyl, quinolinyl, quinoxalinyl and quinazolinyl.
  • the heteroaryl may also be divalent groups derived from the above groups.
  • heteroatom means an atom selected from S, O and N.
  • S or O being oxidized or nitridized are also included.
  • the “3-6 membered ring”, “3-8 membered ring”, “4-6 membered ring” and “4-7 membered ring” described in the present invention refer to chemically feasible ring structures with 3-6 ring atoms, 3-8 ring atoms, 4-6 ring atoms and 4-7 ring atoms; the ring atoms may be optionally selected from C, N, O, S, C( ⁇ O), S( ⁇ O), S( ⁇ O) 2 and S( ⁇ O)( ⁇ NH), and the formed ring structures may be monocyclic, fused polycyclic, saturated, partially saturated or aromatic. Specifically, examples may be the aforementioned groups enumerated as cycloalkyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl.
  • a group/subgroup with the amino as the terminal can be represented by —N(R e ) 2 , wherein R e is each independently selected from hydrogen, the aforementioned C 1-6 alkyl optionally substituted by the substituent A of the present invention, the aforementioned C 2-6 alkenyl optionally substituted by the substituent A of the present invention, the aforementioned C 2-6 alkynyl optionally substituted by the substituent A of the present invention, the aforementioned cycloalkyl optionally substituted by the substituent A of the present invention, the aforementioned cycloalkenyl optionally substituted by the substituent A of the present invention, the aforementioned aryl optionally substituted by the substituent A of the present invention, the aforementioned heteroaryl optionally substituted by the substituent A of the present invention, the aforementioned heterocyclyl optionally substituted by the substituent A of the present invention, the aforementioned heterocyclyl optionally substituted by the substituent A of the present invention, the aforementioned
  • a group/subgroup with an amino as a terminal in a group containing an “amino” means that the amino is bonded with two R e and then connected to other groups.
  • “(C 1-6 alkyl) 2 amino” it corresponds to the case of a group with an amino as a terminal in a group containing “amino”
  • “C 1-6 alkylamino” it corresponds to the case of a group with an amino as a terminal in a group containing “amino”, in which one R e has already represented “C 1-6 alkyl” and the other R e represents the group enumerated above
  • “(C 1-6 alkyl) 2 amino C 1-6 alkyl” the “(C 1-6 alkyl) 2 amino” therein corresponds to the case of a subgroup with an amino as a terminal in a group containing “amino”, that is, the amino is bonded with two C 1-6 alkyl (corresponding to R e ) first and then
  • the two bonds in which may be bonded with R e may form an nitrogen containing heterocyclyl having the definition described above in the present invention.
  • the term “optionally substituted” or “optionally substituted by” means that any portion of the moiety known to those skilled in the art to be available for being substituted may be unsubstituted or substituted by a substituent described in the present invention, wherein if one or more substituents are present, each substituent may be independently selected.
  • substitution the number of substituents is determined according to the number of positions capable of being substituted on a substituted group, and there may be 1 substitution, 2 substitutions, 3 substitutions, 4 substitutions, 5 substitutions, 6 substitutions, 7 substitutions, 8 substitutions or more as long as the number of the positions capable of being substituted on the substituted group is not exceeded.
  • substituents “one or more” substituents indicate that no less than one substituents are present, and the specific number of substituents varies according to a substituted group, and there may be 1 substitution, 2 substitutions, 3 substitutions, 4 substitutions, 5 substitutions, 6 substitutions, 7 substitutions, 8 substitutions or more as long as the number of the positions capable of being substituted on the substituted group is not exceeded.
  • “optionally substituted” added before a group or “optionally substituted by” added after a group indicates that all subgroups in the group can be optionally substituted.
  • the alkyl moiety may be substituted by halogen
  • the aryl moiety may be substituted by halogen
  • both the alkyl moiety and the aryl moiety may be substituted by halogen.
  • the ring structure represents a double bond optionally existing in the ring, and there may be 1, 2 or 3 double bonds, limited to the maximum number of double bonds that may exist in the ring. For example, in a 5 membered ring, one or two double bonds may exist; and in a 6 membered ring, one, two or three double bonds may exist.
  • the “absence” of a certain group may mean that the group itself is absent; for example, for the definition of “R d is absent”, when the ring-forming N atom is connected to adjacent atoms with single bonds and double bonds in a ring, R d is absent in the definition of “NR d ”.
  • the group may also mean that the group is a bond; for example, for the definition of “L 1 is absent” in the present invention, it means that L 1 is a bond enabling the Cy 1 group to directly bond to a carbon atom connected with a R 6 group.
  • the substituent in “optionally substituted by substituents” may be the “substituent A” described in the present invention.
  • the number of substituents is determined according to the number of positions capable of being substituted on a substituted group, and there may be 1 substitution, 2 substitutions, 3 substitutions, 4 substitutions, 5 substitutions, 6 substitutions, 7 substitutions, 8 substitutions or more.
  • the valences of all groups, substituents, chemical bonding sites, atoms, etc. do not violate the common knowledge in the chemical field.
  • carbon atoms are tetravalent
  • nitrogen atoms are trivalent
  • oxygen atoms are bivalent
  • hydrogen atoms are monovalent.
  • the present invention provides a compound shown as formula (I) below or a pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof:
  • R 1 and R 2 are each independently selected from hydrogen and halogen, and R 1 and R 2 are not both hydrogen;
  • R 3 and R 4 are each independently selected from hydrogen and C 1-6 alkyl optionally substituted by a substituent A, or form a 5-10 membered nitrogen containing heterocyclyl optionally substituted by a substituent A along with an N atom connected thereto;
  • R 5 and R 6 are each independently selected from hydrogen and C 1-6 alkyl optionally substituted by a substituent A;
  • L 1 is a bond or —CR′R′′—, —NR′—, —S—, —SO 2 —, —S(O)—, —SONR′—, —SO 2 NR′— or —NR′CONR′—, and R′ and R′′ are each independently selected from hydrogen and C 1-6 alkyl optionally substituted by a substituent A;
  • Cy 1 is a group shown as general formula (A), (a), (b) or (c) below that is unsubstituted or substituted by one or more R a :
  • n is an integer from 0 to 2;
  • Y 1 , Y 2 , Y 3 and Y 4 are each independently selected from CR c R c , NR d , O and S;
  • X 1 , X 2 , X 3 , X 4 , X 9 and X 10 are each independently selected from CR c R c , NR d , O and S, X 5 , X 6 , X 7 and X 8 are each independently selected from CR c R c and NR d , and at least one of X 1 , X 2 and X 3 is NR d ;
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarboxyl, C 1-6 alkyl optionally substituted by one or more R b , C 2-6 alkenyl optionally substituted by one or more R b , C 2-6 alkynyl optionally substituted by one or more R b , C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkylthio optionally substituted by one or more R b , C 1-6 alkylthio C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkylamino optionally substituted by one or more R
  • Cy 2 is each independently selected from 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocyclyl, 6-10 membered aryl and 5-14 membered heteroaryl;
  • each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, amino C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, amino C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylthio, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylaminocarbonyl, (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylcarbonyl, C 1-6 alkylaminosulfonyl, (C 1-6 alkyl) 2 aminosulfonyl, C 1-6 alkylsulfonylamino and C 1-6 al
  • the substituents A are each independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, amino C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, amino C 1-6 alkoxy, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylaminocarbonyl, (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylcarbonyl, C 1-6 alkylsulfonylamino, C 1-6 alkylaminosulfonyl, (C 1-6 alkyl) 2 aminosulfonyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1-6 alkylsulfony
  • R c is absent, or is each independently selected from hydrogen atom when present; or two R c form an oxo group together;
  • R d is absent, or is each independently selected from hydrogen atom when present;
  • R 1 and R 2 are each independently selected from hydrogen and halogen, and R 1 and R 2 are not both hydrogen. In one embodiment of the present invention, R 1 and R 2 are each independently selected from hydrogen, fluorine, chlorine, bromine and iodine, and R 1 and R 2 are not both hydrogen. In one embodiment of the present invention, R 1 and R 2 are each independently selected from hydrogen, fluorine and chlorine, and R 1 and R 2 are not both hydrogen. In one embodiment of the present invention, R 1 is hydrogen, and R 2 is fluorine. In one embodiment of the present invention, R 1 and R 2 form 5-8 nitrogen containing heterocyclyl along with N atoms connected thereto.
  • R 3 and R 4 are each independently selected from hydrogen and C 1-6 alkyl. In one embodiment of the present invention, R 3 and R 4 are each independently selected from hydrogen and C 1-4 alkyl. In one embodiment of the present invention, R 3 and R 4 are each independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl. In one embodiment of the present invention, R 3 and R 4 are hydrogen. In one embodiment of the present invention, R 3 and R 4 form 5-6 membered nitrogen containing heterocyclyl along with N atoms connected thereto. In one embodiment of the present invention, R 3 and R 4 form pyrrolinyl, pyrrolidinyl, piperidyl or morpholinyl along with N atoms connected thereto.
  • R 5 and R 6 are each independently selected from hydrogen and C 1-6 alkyl. In one embodiment of the present invention, R 5 and R 6 are each independently selected from hydrogen and C 1-4 alkyl. In one embodiment of the present invention, R 5 and R 6 are each independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl. In one embodiment of the present invention, R 5 and R 6 are hydrogen.
  • L 1 is a bond or —CR′R′′—, —NR′— or —S—, and R′ and R′′ are each independently selected from hydrogen and C 1-6 alkyl. In one embodiment of the present invention, L 1 is a bond, —NR′— or —S—, and R′ and R′′ are each independently selected from hydrogen and C 1-6 alkyl. In one embodiment of the present invention, L 1 is a bond or —NR′—, and R′ is selected from hydrogen and C 1-6 alkyl. In one embodiment of the present invention, L 1 is a bond.
  • R a when R a is present, at least one R a is connected to any one of Y 1 , Y 2 , Y 3 and Y 4 . In one embodiment of the present invention, for formula (a), when R a is present, at least one R a is connected to any one of Y 1 , Y 2 and Y 3 . In one embodiment of the present invention, for formula (c), at least one R a is present, and at least one R a is connected to any one of X 5 , X 6 , X 7 and X 8 .
  • the Li group is connected to X 1 , X 2 or X 3 in formula (A).
  • the L 1 group is connected to X 1 , X 2 or X 3 in formula (a).
  • the L 1 group is connected to X 1 , X 2 , X 3 or X 4 in formula (c).
  • the L 1 group is connected to an N atom.
  • Cy 1 is a group shown as general formula (A-1), (A-2), (A-3), (a), (b) or (c) below that is unsubstituted or substituted by one or more R a :
  • Cy 1 is a group shown as general formula (A-11), (a-1), (a-2), (b-1), (c-1) or (c-2) below that is unsubstituted or substituted by one or more R a :
  • X 1 , X 2 , X 3 and X 9 are not C ⁇ O.
  • R a when R a is present, at least one Ra is connected to Y 2 . In one embodiment of the present invention, for formula (a-1), when R a is present, at least one R a is connected to Y 2 . In one embodiment of the present invention, for formula (a-2), when R a is present, at least one R a is connected to Y 1 . In one embodiment of the present invention, for formula (b-1), when R a is present, at least one R a is connected to a ring-forming carbon atom. In one embodiment of the present invention, for formulas (c-1) and (c-2), at least one R a is present, and at least one R a is connected to a benzene ring group.
  • n is an integer from 0 to 3. In one embodiment of the present invention, m is 1 or 2. In one embodiment of the present invention, n is an integer from 0 to 2. In one embodiment of the present invention, n is 1 or 2.
  • R c is absent, or is each independently selected from hydrogen atom when present; or two R c form an oxo group together.
  • R d is absent, or is each independently selected from hydrogen atom.
  • Y 1 , Y 2 , Y 3 and Y 4 are each independently selected from CR c R c and NR d . In one embodiment of the present invention, at least one of Y 1 , Y 2 , Y 3 and Y 4 is C ⁇ O. In one embodiment of the present invention, Y 1 , Y 2 and Y 3 are each independently selected from CH 2 , NH, CH and N.
  • X 1 , X 2 , X 3 , X 4 , X 9 and X 10 are each independently selected from CR c R c and NR d , and at least one of X 1 , X 2 and X 3 is N or NR d .
  • X 1 , X 2 , X 3 , X 4 and X 9 are each independently selected from CH 2 , CH, N, NH and C ⁇ O, and at least one of X 1 , X 2 and X 3 is N or NH.
  • X 5 , X 6 , X 7 and X 8 are each independently selected from CR c R c and NR d .
  • Cy 1 is a group shown as general formula (A-11) or (a-1) below that is unsubstituted or substituted by one or more R a :
  • Y 2 and Y 3 are each independently selected from CH 2 , NH, CH and N.
  • X 1 , X 2 and X 3 are each independently selected from CH 2 , CH, N, NH and C ⁇ O, and at least one of X 1 , X 2 and X 3 is N or NH.
  • X 1 and X 2 are each independently selected from CH 2 , CH, N and NH. In one embodiment of the present invention, in formula (a-1), X 1 and X 2 are each independently selected from CH 2 , CH, N and NH. In one embodiment of the present invention, in formulas (A-11) and (a-1), Y 2 is NH. In one embodiment of the present invention, in formulas (A-11) and (a-1), Y 3 is CH 2 or CH. In one embodiment of the present invention, in formulas (A-11) and (a-1), when R a is present, at least one R a is connected to the position Y 2 .
  • the L 1 group in formulas (A-11) and (a-1), is connected to X 1 , X 2 or X 3 . In one embodiment of the present invention, in formulas (A-11) and (a-1), the L 1 group is connected to an N atom.
  • Cy 1 is one of the following groups that is unsubstituted or substituted by one or more R a :
  • Cy 1 is a group shown as general formula (b-1) below that is unsubstituted or substituted by one or more R a :
  • X 1 , X 2 , X 3 and X 9 are each independently selected from CH 2 , CH, N and NH, and at least one of X 1 , X 2 and X 3 is N or NH.
  • the Li group is connected to the N atom in formula (b-1). In one embodiment of the present invention, in formula (b-1), when R a is present, at least one R a is connected to the carbon atom of formula (b-1).
  • Cy 1 is one of the following groups that is unsubstituted or substituted by one or more R a :
  • Cy 1 is a group shown as general formula (c-1) below that is substituted by one or more R a :
  • X 1 , X 2 and X 3 are each independently selected from CH 2 , CH, N, NH and C ⁇ O, and at least one of X 1 , X 2 and X 3 is N or NH.
  • At least one R a is connected to the benzene ring moiety in formula (c-1).
  • the L 1 group is connected to X 1 , X 2 or X 3 .
  • the L 1 group is connected to the N atom in formula (c-1).
  • Cy 1 is the following group that is substituted by one or more substituent R a :
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkylthio optionally substituted by one or more R b , C 1-6 alkylthio C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkylamino optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino optionally substituted by one or more R b , C 1-6 alkylamino C 1-6 alkyl optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino optionally substitute
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkylamino optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino optionally substituted by one or more R b , C 1-6 alkylamino C 1-6 alkyl optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkylaminocarbonyl optionally substituted by one or more R b , (C 1-6 alkyl)
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkylamino optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino optionally substituted by one or more R b , C 1-6 alkylamino C 1-6 alkyl optionally substituted by one or more R b , (C 1-6 alkyl) 2 amino C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkylaminocarbonyl optionally substituted by one or more R b , (C 1-6 alkyl)
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkoxy C 1-6 alkoxy optionally substituted by one or more R b , C 1-6 alkylamino optionally substituted by one or more R b , C 1-6 alkylamino C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkylaminocarbonyl optionally substituted by one or more R b , C 1-6 alkylaminocarbonyl C 1-6 alkyl optionally substituted by one or more R b , C 1-6 alkylaminocarbonyl C 1-6 alkyl optionally substituted by one or more R b ,
  • each R a is independently selected from halogen, cyano, C 1-6 alkyl optionally substituted by at least one of halogen, C 1-6 alkyl, C 1-6 alkoxy and 3-6 membered cycloalkyl, 3-8 membered cycloalkyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, phenyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, and 5-6 membered heteroaryl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy.
  • R a is each independently selected from C 1-6 alkyl optionally substituted by halogen; halogen; aminocarbonyl; C 1-6 alkylaminocarbonyl optionally substituted by halogen; (C 1-6 alkyl) 2 aminocarbonyl optionally substituted by halogen; 3-8 membered cycloalkylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy; phenylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy; 5-6 membered heteroarylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy; and 5-10 membered heterocyclylcarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy.
  • each R a is independently selected from hydroxyl, amino, cyano, halogen, aminocarbonyl, C 1-4 alkyl optionally substituted by one or more R b , C 1-4 alkoxy optionally substituted by one or more R b , C 1-4 alkoxy C 1-4 alkyl optionally substituted by one or more R b , C 1-4 alkoxy C 1-4 alkoxy optionally substituted by one or more R b , C 1-4 alkylthio optionally substituted by one or more R b , C 1-4 alkylthio C 1-4 alkyl optionally substituted by one or more R b , C 1-4 alkylamino optionally substituted by one or more R b , (C 1-4 alkyl) 2 amino optionally substituted by one or more R b , C 1-4 alkylamino C 1-4 alkyl optionally substituted by one or more R b , (C 1-4 alkyl) 2 amino optionally substituted by one or more R
  • R a is each independently selected from halogen, cyano, C 1-4 alkyl optionally substituted by at least one of halogen, C 1-6 alkyl, C 1-6 alkoxy and 3-5 membered cycloalkyl, 3-5 membered cycloalkyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, phenyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, and 5-6 membered nitrogen heteroaryl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy.
  • R a is each independently selected from fluorine; chlorine; bromine; cyano; methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl optionally substituted by at least one of halogen, C 1-6 alkyl, C 1-6 alkoxy and 3-5 membered cycloalkyl; cyclopropyl, cyclobutyl and cyclopentyl optionally substituted by at least one of halogen and C 1-6 alkyl; phenyl optionally substituted by at least one of halogen and C 1-6 alkyl; and pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl optionally substituted by at least one of halogen and C 1-6 alkyl.
  • each R a is independently selected from aminocarbonyl, C 1-4 alkylaminocarbonyl optionally substituted by halogen, (C 1-4 alkyl) 2 aminocarbonyl optionally substituted by halogen, 3-5 membered cycloalkylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, phenylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy and 5-6 membered nitrogen containing heterocyclylcarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy.
  • R a is each independently selected from aminocarbonyl, methylaminocarbonyl optionally substituted by halogen, ethylaminocarbonyl optionally substituted by halogen, propylaminocarbonyl optionally substituted by halogen, isopropylaminocarbonyl optionally substituted by halogen, n-aminocarbonyl optionally substituted by halogen, isobutylaminocarbonyl optionally substituted by halogen, sec-butylaminocarbonyl optionally substituted by halogen, tert-butylaminocarbonyl optionally substituted by halogen, cyclopropylaminocarbonyl optionally substituted by at least one of halogen and C 1-6 alkyl, cyclobutylaminocarbonyl optionally substituted by at least one of halogen and C 1-6 alkyl, cyclopentylaminocarbonyl optionally substituted by at least one of halogen
  • R a is each independently selected from aminocarbonyl, methylaminocarbonyl optionally substituted by halogen, ethylaminocarbonyl optionally substituted by halogen, propylaminocarbonyl optionally substituted by halogen, isopropylaminocarbonyl optionally substituted by halogen, n-aminocarbonyl optionally substituted by halogen, isobutylaminocarbonyl optionally substituted by halogen, sec-butylaminocarbonyl optionally substituted by halogen, tert-buty 1 aminocarbonyl optionally substituted by halogen, cyclopropylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, cyclobutylaminocarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, cyclopentylaminocarbonyl, C 1-6 alky
  • R a is each independently selected from azetidinylcarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, pyrrolidinylcarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, piperidylcarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, piperazinylcarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy and morpholinylcarbonyl optionally substituted by at least one of halogen, C 1-6 alkyl and C 1-6 alkoxy, the ring-forming nitrogen atom located on the ring is bonded with carbonyl (C ⁇ O).
  • Cy 2 is each independently selected from 3-8 membered cycloalkyl, 5-10 membered heterocyclyl, phenyl, naphthyl and 5-10 membered heteroaryl. In one embodiment of the present invention, Cy 2 is each independently selected from 3-6 membered cycloalkyl, 5-6 membered heterocyclyl, phenyl, naphthyl and 5-6 membered heteroaryl.
  • each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl, C 1-6 alkoxy, amino C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, amino C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylthio, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylaminocarbonyl, (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkylcarbonylamino and C 1-6 alkylcarbonyl.
  • each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, aminocarbonyl, C 1-6 alkyl, C 1-6 alkoxy, amino C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, amino C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylthio, C 1-6 alkylamino, C 1-6 alkylaminocarbonyl, C 1-6 alkylcarbonylamino and C 1-6 alkylcarbonyl.
  • each R b is independently selected from hydroxyl, amino, cyano, halogen, aminocarbonyl, C 1-4 alkyl, CM alkoxy, amino C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy C 1-4 alkyl, C 1-4 alkoxy C 1-4 alkoxy, amino C 1-4 alkoxy, C 1-4 haloalkoxy, C 1-4 alkylthio, C 1-4 alkylamino, (C 1-4 alkyl) 2 amino, C 1-4 alkylaminocarbonyl, (C 1-4 alkyl) 2 aminocarbonyl, C 1-4 alkylcarbonylamino and C 1-4 alkylcarbonyl.
  • the substituents A are each independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1-6 alkyl, C 1-6 alkoxy, amino C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, amino C 1-6 alkoxy, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylaminocarbonyl, (C 1-6 alkyl) 2 aminocarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylcarbonyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1-6 alkylthio, 3-8 membered cycloalkyl, 5-10 membered heterocyclyl, phenyl, naphthyl, 5-10 membered heteroaryl and oxo.
  • the substituents A are each independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1-4 alkyl, C 1-4 alkoxy, amino C 1-4 alkyl, C 1-4 alkoxy C 1-4 alkyl, C 1-4 alkoxy C 1-4 alkoxy, amino C 1-4 alkoxy, C 1-4 alkylamino, (C 1-4 alkyl) 2 amino, C 1-4 alkylaminocarbonyl, (C 1-4 alkyl) 2 aminocarbonyl, C 1-4 alkylcarbonylamino, C 1-4 alkylcarbonyl, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 1-4 alkylthio, 3-6 membered cycloalkyl, 5-10 membered heterocyclyl, phenyl, naphthyl, 5-10 membered heteroaryl and oxo.
  • N atom is bonded with the aforementioned group recorded in the present invention, or the N atom is contained in a nitrogen containing heterocyclic ring) is bonded with the ring structure.
  • an aminocarbonyl group in formulas (b) and (b-1), an aminocarbonyl group
  • N atom is bonded with the aforementioned group recorded in the present invention, or the N atom is contained in a nitrogen containing heterocyclic ring) is connected to the ring-forming carbon atom.
  • X 5 , X 6 , X 7 or X 8 is bonded with an aminocarbonyl group
  • N atom is bonded with the aforementioned group recorded in the present invention, or the N atom is contained in a nitrogen containing heterocyclic ring).
  • N atom is bonded with the aforementioned group recorded in the present invention, or the N atom is contained in a nitrogen containing heterocyclic ring.
  • an aminocarbonyl group in formulas (c-1) and (c-2), an aminocarbonyl group
  • N atom is bonded with the aforementioned group recorded in the present invention, or the N atom is contained in a nitrogen containing heterocyclic ring) is connected to a benzene ring structure.
  • X 5 , X 6 , X 7 and X 8 each independently represent CH.
  • X 5 , X 6 , X 7 and X 8 are not C ⁇ O.
  • Y 1 is C ⁇ O
  • Y 2 represents NR d .
  • the ring-forming nitrogen atom located on the ring is bonded with carbonyl (C ⁇ O) to form aminocarbonyl.
  • the compound of the present invention or the pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof is provided, and the compound is selected from:
  • a pharmaceutical composition which comprises the compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof described above, and also optionally comprises one or more pharmaceutically acceptable carriers.
  • a method for preventing and/or treating diseases related to or mediated by the SSAO/VAP-1 protein wherein the pharmaceutical composition of the compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof described above or the pharmaceutical composition described above is administered to a subject in need of treatment at an effective dose.
  • a compound of formula I or a pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof is provided:
  • R 1 and R 2 are each independently selected from hydrogen and halogen, and R 1 and R 2 are not both hydrogen;
  • R 3 and R 4 are each independently selected from hydrogen and C 1-6 alkyl, or form a 5-10 membered nitrogen containing heterocycle optionally substituted by a substituent along with a N atom connected thereto;
  • R 5 and R 6 are each independently selected from hydrogen and C 1-6 alkyl
  • L 1 is absent, or is —Cr′R′′—, —N—, —O—, —S—, —SO 2 —, S(O), —SONR′—, —SO 2 NR′— or —NR′CONR′—, and R′ and R′′ are each independently selected from hydrogen and C 1-6 alkyl;
  • Cy 1 is a group that is unsubstituted or substituted by one or more R a shown in general formula (A), (a), (b) or (c) below:
  • n is an integer from 0 to 2;
  • Y 1 , Y 2 , Y 3 and Y 4 are each independently selected from CH 2 , CH, NH, N, O, S and C ⁇ O;
  • X 1 , X 2 , X 3 , X 4 , X 9 and X 10 are each independently selected from CH 2 , CH, N, O, S, NH and C ⁇ O, X 5 , X 6 , X 7 and X 8 are each independently selected from CH and N, and at least one of X 1 , X 2 and X 3 is N or NH;
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, and C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 alkylthio C 1-6 alkyl, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylamino C 1-6 alkyl, C 1-6 alkylaminocarbonyl, C 1-6 alkylaminocarbonyl C 1-6 alkyl, C 1-6 alkylcarbonylamino, C 1-6 alkylcarbonylamino C 1-6 alkyl, (C 1-6 alkyl) 2 amino C 1-6 alkyl, C 1-6 alkylcarbonyl, C 1-6 alkylcarbonylamino C 1-6 alkyl, (C
  • Cy 2 is 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocyclyl, aryl or 5-14 membered heteroaryl;
  • each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylaminocarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylcarbonyl, C 1-6 alkylaminosulfonyl, C 1-6 alkylsulfonylamino and C 1-6 alkylsulfonyl; with the proviso that when Cy 1 is formula (c), formula (c) is substituted by one or more R a ;
  • a compound of formula I below or a pharmaceutically acceptable salt, ester, stereoisomer or tautomer thereof is provided:
  • R 1 and R 2 are each independently selected from hydrogen and halogen, and R 1 and R 2 are not both hydrogen;
  • R 3 and R 4 are each independently selected from hydrogen and C 1-6 alkyl, or form a 5-10 membered nitrogen containing heterocycle optionally substituted by a substituent along with a N atom connected thereto;
  • R 5 and R 6 are each independently selected from hydrogen and C 1-6 alkyl
  • L 1 is absent, or is —Cr′R′′—, —N—, —O—, —S—, —SO 2 —, S(O), —SONR′—, —SO 2 NR′— or —NR′CONR′—, and R′ and R′′ are each independently selected from hydrogen and C 1-6 alkyl;
  • Cy 1 is a group that is unsubstituted or substituted by one or more R a shown in general formula (A-1), (A-2), (A-3), (a), (b) or (c) below:
  • n is an integer from 0 to 2;
  • Y 1 , Y 2 , Y 3 and Y 4 are each independently selected from CH 2 , CH, NH, N, O, S and C ⁇ O;
  • X 1 , X 2 , X 3 , X 4 , X 9 and X 10 are each independently selected from CH 2 , CH, N, O, S, NH and C ⁇ O, X 5 , X 6 , X 7 and X 8 are each independently selected from CH and N, and at least one of X 1 , X 2 and X 3 is N or NH;
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, and C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 alkylthio C 1-6 alkyl, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylamino C 1-6 alkyl, C 1-6 alkylaminocarbonyl, C 1-6 alkylaminocarbonyl C 1-6 alkyl, C 1-6 alkylcarbonylamino, C 1-6 alkylcarbonylamino C 1-6 alkyl, (C 1-6 alkyl) 2 amino C 1-6 alkyl, C 1-6 alkylcarbonyl, C 1-6 alkylcarbonylamino C 1-6 alkyl, (C
  • Cy 2 is 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocyclyl, aryl or 5-14 membered heteroaryl;
  • each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, C 1-6 alkylaminocarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylcarbonyl, C 1-6 alkylaminosulfonyl, C 1-6 alkylsulfonylamino and C 1-6 alkylsulfonyl;
  • R 1 and R 2 are each independently selected from hydrogen and halogen, and R 1 and R 2 are not both hydrogen;
  • R 3 and R 4 are each independently selected from hydrogen and C 1-6 alkyl
  • R 5 and R 6 are each independently selected from hydrogen and C 1-6 alkyl
  • L 1 is absent, or is —CR′R′′—, —N—, —O— or —S—, and R′ and R′′ are each independently selected from hydrogen and C 1-6 alkyl;
  • Cy 1 is a group that is unsubstituted or substituted by one or more R a shown in general formula (A-1), (A-2), (A-3), (a), (b) or (c) below:
  • n is an integer from 0 to 2;
  • Y 1 , Y 2 , Y 3 and Y 4 are each independently selected from CH 2 , CH, NH, N and C ⁇ O;
  • X 1 , X 2 , X 3 , X 4 , X 9 and X 10 are each independently selected from CH 2 , CH, N, NH and C ⁇ O, X 5 , X 6 , X 7 and X 8 are each independently selected from CH and N, and at least one of X 1 , X 2 and X 3 is N or NH;
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, and C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 alkylthio C 1-6 alkyl, C 1-6 alkylamino, C 1-6 alkylamino C 1-6 alkyl, C 1-6 alkylaminocarbonyl, C 1-6 alkylaminocarbonyl C 1-6 alkyl, C 1-6 alkylcarbonylamino, C 1-6 alkylcarbonylamino C 1-6 alkyl, C 1-6 alkylcarbonyl, C 1-6 alkylcarbonyl C 1-6 alkyl, Cy 2 , Cy 2 -C 1-6 alkyl, Cy 2 -C 1-6 alkoxy, Cy 2 -carbonyl and Cy 2 -aminocarbonyl unsubstituted
  • Cy 2 is 3-8 membered cycloalkyl, 5-10 membered heterocyclyl, phenyl or 5-10 membered heteroaryl;
  • each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 alkylamino, C 1-6 alkylaminocarbonyl, C 1-6 alkylcarbonylamino and C 1-6 alkylcarbonyl;
  • Cy 1 is a group that is unsubstituted or substituted by one or more R a shown in general formula (A-11), (a-1), (a-2), (b-1), (c-1) or (c-2) below:
  • n is an integer that is 1 or 2;
  • Y 1 , Y 2 and Y 3 are each independently selected from CH 2 , CH, NH and N;
  • X 1 , X 2 , X 3 , X 4 and X 9 are each independently selected from CH 2 , CH, N, NH and C ⁇ O, and at least one of X 1 , X 2 and X 3 is N or NH;
  • Cy 1 is a group that is unsubstituted or substituted by one or more R a shown in general formula (A-11) or (a-1) below:
  • n is an integer that is 1 or 2;
  • Y 2 and Y 3 are each independently selected from CH 2 , CH, NH and N;
  • X 1 , X 2 and X 3 are each independently selected from CH 2 , CH, N and NH, and at least one of X 1 , X 2 and X 3 is N or NH;
  • R 1 and R 2 are each independently selected from hydrogen and halogen, and R 1 and R 2 are not both hydrogen;
  • R 3 and R 4 are each independently selected from hydrogen and C 1-6 alkyl
  • R 5 and R 0 are each independently selected from hydrogen and C 1-6 alkyl
  • Cy 1 is one of the following groups unsubstituted or substituted by one or more R a :
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, and C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, C 1-6 alkylamino, C 1-6 alkylamino C 1-6 alkyl, C 1-6 alkylaminocarbonyl, C 1-6 alkylaminocarbonyl C 1-6 alkyl, C 1-6 alkylcarbonylamino, C 1-6 alkylcarbonylamino C 1-6 alkyl, C 1-6 alkylcarbonyl, C 1-6 alkylcarbonyl C 1-6 alkyl, Cy 2 , Cy 2 -C 1-6 alkyl, Cy 2 -C 1-6 alkoxy, Cy 2 -carbonyl and Cy 2 -aminocarbonyl unsubstituted or substituted by one or more substituents R b , and Cy 2 is 3-8 membered
  • each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 alkylamino, C 1-6 alkylaminocarbonyl, C 1-6 alkylcarbonylamino and C 1-6 alkylcarbonyl;
  • Cy 2 represents a double bond optionally present in the ring structure; and preferably, Cy 2 is 3-6 membered cycloalkyl, 5-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl.
  • Cy 1 is a group that is unsubstituted or substituted by one or more R a shown in general formula (b-1) below:
  • X 1 , X 2 , X 3 and X 9 are each independently selected from CH 2 , CH, N and NH, and at least one of X 1 , X 2 and X 3 is N or NH;
  • R 1 and R 2 are each independently selected from hydrogen and halogen, and R 1 and R 2 are not both hydrogen;
  • R 3 and R 4 are each independently selected from hydrogen and C 1-6 alkyl
  • R 5 and R 0 are each independently selected from hydrogen and C 1-6 alkyl
  • Cy 1 is one of the following groups unsubstituted or substituted by one or more R a :
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, and C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, C 1-6 alkylamino, C 1-6 alkylamino C 1-6 alkyl, C 1-6 alkylaminocarbonyl, C 1-6 alkylaminocarbonyl C 1-6 alkyl, C 1-6 alkylcarbonylamino, C 1-6 alkylcarbonylamino C 1-6 alkyl, C 1-6 alkylcarbonyl, C 1-6 alkylcarbonyl C 1-6 alkyl, Cy 2 , Cy 2 -C 1-6 alkyl, Cy 2 -C 1-6 alkoxy, Cy 2 -carbonyl and Cy 2 -aminocarbonyl unsubstituted or substituted by one or more substituents R b , and
  • Cy 2 is 3-8 membered cycloalkyl, 5-10 membered heterocyclyl, phenyl or 5-10 membered heteroaryl;
  • each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 alkylamino, C 1-6 alkylaminocarbonyl, C 1-6 alkylcarbonylamino and C 1-6 alkylcarbonyl.
  • Cy 1 is one of the following groups unsubstituted or substituted by one or more R a :
  • R 1 and R 2 are each independently selected from hydrogen and fluorine, and R 1 and R 2 are not both hydrogen.
  • Cy 1 is one of the following groups substituted by one or more R a :
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, and C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylaminocarbonyl, Cy 2 , Cy 2 -carbonyl and Cy 2 -aminocarbonyl unsubstituted or substituted by one or more substituents R b , and
  • Cy 2 is 3-6 membered cycloalkyl, 5-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl.
  • each R b is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, C 1-6 alkyl and C 1-6 alkoxy.
  • Cy 1 is one of the following groups substituted by one or more R a :
  • each R a is independently selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, and C 1-6 alkyl and 3-6 membered cycloalkyl unsubstituted or substituted by one or more substituents R a .
  • each R b is independently selected from hydroxyl, amino, cyano, nitro and halogen.
  • the “pharmaceutically acceptable salt” described in the present invention refers to a pharmaceutically acceptable addition salt of acid or base of the compound of formula I or an addition salt of a solvate thereof.
  • an acidic functional group such as —COOH, —OH, —SO 3 H, etc.
  • the acidic functional group may be a salt formed with an appropriate inorganic or organic cation (base), including a salt formed with alkali metal, alkaline earth metal or the like, an ammonium salt, and a salt formed with a nitrogenous organic base.
  • the basic functional group may be a salt formed with an appropriate inorganic or organic anion (acid), including a salt formed with an inorganic acid salt or organic acid.
  • Such a “pharmaceutically acceptable salt” includes, but is not limited to, acid salts such as hydrochloride, hydrobromide, hydriodate, sulfate, phosphate, nitrate, benzene sulfonate, benzoate, p-toluene sulfonate, 2,3-dihydroxysuccinate, camphorsulfonate, citrate, methanesulfonate, ethanesulfonate, propanesulfonate, fumarate, gluconate, glutamate, hydroxyethylsulfonate, lactate, maleate, malate, mandelate, muconate, pamoate, pantothenate, succinate, tartrate and the like, preferably benzoate, benzenesulfonate, p-toluene sulfonate, methanesulfonate, citrate, maleate, fumarate, tartrate, alkanoic acid (HO
  • the “pharmaceutically acceptable salt” also includes, but is not limited to, salts formed by the following bases: arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, meglumine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine and tromethamine; and in addition, the “pharmaceutically acceptable salt” may also be lithium salt, sodium salt, potassium salt, calcium salt, magnesium salt, zinc salt, barium salt, aluminum salt, ferric salt, copper salt, ferrous salt, manganese salt
  • the “pharmaceutically acceptable ester” of the compound of the present invention refers to an ester of the compound of the present invention that is hydrolyzed in vivo, and includes an ester that can be easily decomposed in the human body to leave the parent compound or the salt thereof.
  • Suitable ester groups include, for example, ester groups derived from pharmaceutically acceptable aliphatic carboxylic acids (in particular alkanoic acid, alkenoic acid, cyclic alkanoic acid and alkanoic diacid), wherein each alkyl or alkenyl preferably has six or less carbon atoms.
  • Representative examples of a specific ester include, but are not limited to, formate, acetate, propionate, butyrate, acrylate and ethylsuccinate.
  • amino-protecting group refers to a chemical group that is connected to the amino group and can be easily removed under a certain condition, and includes, but is not limited to, alkoxycarbonyl groups, acyl groups and alkyl groups, such as tert-butoxycarbonyl, benzyloxycarbonyl, fluorenylmethoxycarbonyl, allyloxycarbonyl, phthaloyl, benzyl, p-methoxybenzyl, triphenylmethyl, etc.
  • alkoxycarbonyl groups such as tert-butoxycarbonyl, benzyloxycarbonyl, fluorenylmethoxycarbonyl, allyloxycarbonyl, phthaloyl, benzyl, p-methoxybenzyl, triphenylmethyl, etc.
  • Those skilled in the art can carry out appropriate selection and operation according to the common textbook Greene's Protective Groups in Organic Synthesis (4 th edition) in the art.
  • phrases “pharmaceutically acceptable” means that the substance or composition must be pharmaceutically and/or toxicologically compatible with other ingredients contained in the preparation and/or the pharmaceutical composition.
  • the “isomers” described in the present invention include a stereoisomer and a tautomer.
  • the stereoisomer means that an enantiomer will be produced when an asymmetric carbon atom is present in a compound, or that a cis-trans isomer will be produced when a carbon-carbon double bond or a ring structure is present in a compound.
  • tautomer means a functional group isomer that is produced due to the rapid shifting of a certain atom between two positions in a molecule, and the tautomer is a special functional group isomer.
  • a tautomer of a carbonyl compound comprising ⁇ -H may be:
  • T, T 1 and T 2 are each independently selected from any group that meets the bonding rule of the compound.
  • the “tautomer” may also be, for example, other prototropic tautomers, specifically such as a phenol-keto tautomer, a nitroso-oximino tautomer and an imine-enamine tautomer. However, it is not limited to this, and those skilled in the art can easily judge the existence of a tautomer and a specific form thereof in a compound.
  • the pharmaceutical composition of the present invention comprises at least one of the compound of formula I and a pharmaceutically acceptable salt, ester, stereoisomer and tautomer thereof, and optionally one or more pharmaceutically acceptable carriers.
  • composition of the present invention can be administered to a patient or subject in need of prophylaxis and/or treatment in any suitable manner known in the art, for example, oral, parenteral (including subcutaneous, intramuscular, intravenous, intra-arterial, intradermal, intrathecal, and epidural), transdermal, rectal, nasal, transpulmonary, topical (including buccal and sublingual), vaginal, intraperitoneal, intrapulmonary, intranasal and other administrations.
  • parenteral including subcutaneous, intramuscular, intravenous, intra-arterial, intradermal, intrathecal, and epidural
  • transdermal rectal
  • nasal, transpulmonary topical (including buccal and sublingual)
  • vaginal intraperitoneal, intrapulmonary, intranasal and other administrations.
  • the pharmaceutical composition of the present invention can be formulated into a conventional solid preparation, such as tablet, capsule, pill, granule, etc., and can also be formulated into an oral liquid preparation, such as oral solution, oral suspension, syrup, etc.
  • an oral preparation such as oral solution, oral suspension, syrup, etc.
  • suitable excipient, diluent, sweetener, solubilizer, lubricant, binder, tablet disintegrant, stabilizer, preservative and encapsulating material may be added.
  • the pharmaceutical composition can be formulated into an injection, including a solution injection, a sterile powder for injection and a concentrated solution for injection.
  • the injection can be produced by a conventional method existing in the pharmaceutical field, and during the preparation process, no additive may be added, or an appropriate additive may be added according to the property of the medicament.
  • the pharmaceutical composition can be formulated into a suppository and the like.
  • the pharmaceutical composition can be formulated into a inhalant, spray or the like.
  • suitable solid carriers include, but are not limited to, cellulose, glucose, lactose, mannitol, magnesium stearate, magnesium carbonate, sodium carbonate, sodium saccharin, sucrose, dextrin, talc, starch, pectin, gelatin, tragacanth, arabic gum, sodium alginate, p-hydroxylbenzoate, methylcellulose, sodium carboxymethyl cellulose, low melting wax, cocoa butter, etc.
  • Suitable liquid carriers include, but are not limited to, water, ethanol, polyol (such as glycerol, propylene glycol, liquid polyethylene glycol, etc.), vegetable oil, glyceride, and mixtures thereof.
  • compositions of the present invention are generally known.
  • the pharmaceutical composition of the present invention is prepared by known methods, including conventional mixing, granulating, tableting, coating, dissolving or lyophilizing.
  • the pharmaceutical formulation is preferably in unit dosage form.
  • the formulation is subdivided into unit dosages containing an appropriate quantity of active components.
  • the unit dosage form can be packaged into packages containing a discrete quantity of formulation, such as packaged tablets, capsules, or powders in a vial or an ampoule.
  • Dosage of a medicament depends on various factors, including the age, weight and state of a patient, as well as the route of administration. The precise dosage administered is determined based on the judgment of a treating physician.
  • the usual dosage for administration of the active compound may be, for example, about 0.01 to about 100 mg/day, about 0.05 to about 75 mg/day, about 0.1 to about 50 mg/day, or about 5 to about 10 mg/day.
  • the desired dosage also depends on the specific compound employed, the severity of the disease, the route of administration, the weight and health status of a patient, and the judgment of a treating physician.
  • the compound of the present invention also includes a compound in which one or more hydrogen atoms, fluorine atoms, carbon atoms, nitrogen atoms, oxygen atoms and sulfur atoms are replaced with radioisotopes or stable isotopes.
  • labeled compounds can be used for metabolic or pharmacokinetic studies, biological analysis as ligands for receptors, etc.
  • the compound of the present invention can be used for treating and/or preventing diseases related to or mediated by the SSAO/VAP-1 protein, which comprises administering the compound of the present invention to a subject.
  • the pharmaceutical composition comprising the compound of the present invention can be used for treating and/or preventing diseases related to or mediated by the SSAO/VAP-1 protein, which comprises administering the compound of the present invention to a subject.
  • the compound of the present invention can be prepared by a variety of methods including standard chemical methods. Unless otherwise stated, any variable defined above will continue to have the meaning defined above. Exemplary general synthesis methods are elaborated in the following schemes, and can be easily modified to prepare other compounds of the present invention. Those skilled in the art can perform the following reactions according to a conventional method (such as Organic Synthesis (2 nd edition), Michael B. Smith etc.) taught in the art. The specific compounds of the present invention were specifically prepared in examples.
  • the compound of general formula (I) was obtained through a reaction between formula (SM1) and formula (SM2),
  • X 1 is a leaving group, including but not limited to halogen or sulfonate.
  • R 3 and R 4 are hydrogen, in the process of preparation, the hydrogen on N in
  • G 1 and G 2 are amino-protecting groups.
  • amino-protecting groups are protecting groups commonly used by those skilled in the art, such as tert-butoxycarbonyl, benzyloxycarbonyl, tert-butyl, 9-fluorenylmethoxycarbonyl, allyloxycarbonyl, trifluoroacetyl, chloroacetyl, triphenylmethyl, tetrahydropyranyl, 4-methoxybenzyl, 2,4-dimethoxybenzyl, o-nitrobenzenesulfonyl, and phthaloyl.
  • the method for protecting and deprotecting amino groups can also be performed through methods known to those skilled in the art. For example, reference can be made to the steps recorded in Protective Groups in Organic Synthesis (3 rd edition).
  • the compound of general formula (I′) was prepared through the following steps:
  • Formula (SM1) was dissolved in organic solvent 1 , and the solution was added with a suitable base to react with formula (SM2-a) to give formula (II-a);
  • the compound of general formula (I′) was prepared through the following steps:
  • G 2 is selected from tert-butoxycarbonyl, benzyloxycarbonyl, tert-butyl, 9-fluorenylmethoxycarbonyl, allyloxycarbonyl, trifluoroacetyl, chloroacetyl, triphenylmethyl, tetrahydropyranyl, 4-methoxybenzyl, 2,4-dimethoxybenzyl, and o-nitrobenzenesulfonyl.
  • Formula (SM1) was dissolved in organic solvent 1 , and the solution was added with formula (SM2-c) and a base to give formula (II-c);
  • the compound of general formula (I′) was prepared through the following steps:
  • the organic solvent 1 was DMF, DMA, ACN, methanol, ethanol, isopropanol, or THF.
  • the organic solvent 2 was methanol, ethanol, or isopropanol.
  • the base was sodium hydride, cesium carbonate, or potassium carbonate.
  • the deprotecting agent was hydrochloric acid, trifluoroacetic acid, hydrobromic acid, trimethyliodosilane, or the like.
  • a phase-transfer catalyst may be added to give the target compound during the reaction, and the phase-transfer catalyst may be a catalyst commonly used in the art, including but not limited to, for example, copper acetate, copper chloride, palladium on carbon, ferric chloride, palladium acetate, [1,1′-bis(diphenylphosphino)ferrocene]palladium dichloride, tetrabutylammonium bromide, benzyltriethylammonium chloride, tetrabutylammonium chloride, etc.
  • a catalyst commonly used in the art including but not limited to, for example, copper acetate, copper chloride, palladium on carbon, ferric chloride, palladium acetate, [1,1′-bis(diphenylphosphino)ferrocene]palladium dichloride, tetrabutylammonium bromide, benzyltriethylammonium chloride, tetrabuty
  • suitable deprotecting agent refers to a reagent which those skilled in the art use to perform a deprotection reaction by selecting a corresponding acid, base or oxidant according to different types of amino-protecting groups G 1 and G 2 in a chemical structure. Those recorded in Protective Groups in Organic Synthesis (3 rd edition) may be adopted.
  • the “acid” may be acids commonly used in the art, including organic acids and inorganic acids.
  • the organic acids may include, for example, formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, ascorbic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid and ethylsulfonic acid; and the inorganic acids may include, for example, hydrochloric acid, sulfuric acid, nitric acid, carbonic acid, hydrobromic acid, phosphoric acid, hydroiodic acid, etc. Hydrochloric acid is preferred.
  • the “base” may be bases commonly used in the art, including organic bases and inorganic bases.
  • the organic bases may include, for example, methylamine, ethylamine, propylamine, N,N-diisopropylethylamine, trimethylamine, triethylamine, N-methyl morpholine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, diethanolamine, ethylenediamine, pyridine, methylpyridine, quinoline, etc.
  • the inorganic bases may include, for example, hydroxides, carbonates and bicarbonates of alkali metals (such as lithium, sodium, potassium and cesium); hydroxides, carbonates and bicarbonates of alkaline earth metals (magnesium, calcium, strontium and barium); sodium tert-butoxide, potassium tert-butoxide, sodium ethoxide, etc.
  • the “oxidant” may be an oxidant commonly used in the art, including but not limited to ceric ammonium nitrate, 2,3-dichloro-5,6-dicyano-p-benzoquinone, copper chloride, manganese dioxide, permanganate, dichromate, peroxyacetic acid, peroxybenzoic acid, etc.
  • the “organic solvent 1 ” refers to a single or mixed organic solvent commonly used in the art, including but not limited to ethers, alkanes, haloalkanes, aromatic hydrocarbons, alcohols, etc.
  • the organic solvent may be N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, aromatic hydrocarbons (such as toluene, benzene, dimethylbenzene, trimethylbenzene, etc.), saturated hydrocarbons (such as cyclohexane, hexane, etc.), halohydrocarbons (such as dichloromethane, chloroform, 1,2-dichloroethane, etc.), ethers (such as tetrahydrofuran, diethyl ether, dioxane, 1,2-dimethoxyethane, etc.), esters (such as methyl acetate, ethyl acetate, etc.), ketones (such as methyl a
  • the “organic solvent 2 ” refers to a single or mixed organic solvent commonly used in the art, including but not limited to ethers, alkanes, haloalkanes, aromatic hydrocarbons, alcohols, etc.
  • the organic solvent may be N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, aromatic hydrocarbons (such as toluene, benzene, dimethylbenzene, trimethylbenzene, etc.), saturated hydrocarbons (such as cyclohexane, hexane, etc.), halohydrocarbons (such as dichloromethane, chloroform, 1,2-dichloroethane, etc.), ethers (such as tetrahydrofuran, diethyl ether, dioxane, 1,2-dimethoxyethane, etc.), esters (such as methyl acetate, ethyl acetate, etc.), ketones (such as methyl a
  • the reaction temperature can be adjusted as required, such as high temperature, room temperature, low temperature, etc.
  • High temperature usually refers to a temperature higher than 30° C., and heating can be performed when necessary.
  • Room temperature usually refers to 15° C. to 30° C.
  • Low temperature usually refers to a temperature lower than 15° C., and cooling can be performed when necessary.
  • reaction conditions are not specified in the examples, conventional conditions or conditions recommended by the manufacturers shall be adopted.
  • the adopted reagents or instruments, without manufacturers, are all commercially-available conventional products.
  • the temperature is expressed in Celsius (° C.), and operation is performed at room temperature;
  • the reaction process is tracked by thin-layer chromatography (TLC) or LC-MS;
  • the final product has clear proton nuclear magnetic resonance spectroscopy ( 1 H-NMR) data and mass spectrometry (MS) data.
  • DIPEA N,N-diisopropylethylamine
  • PE petroleum ether
  • HATU 2-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate
  • Step 3 Synthesis of (E)-2-(2-((5-cyclopropyl-4-oxo-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)-3-fluoroallyl)isoindole-1,3-dione
  • Step 4 Synthesis of (E)-2-(2-(aminomethyl)-3-fluoroallyl)-5-cyclopropyl-2,5,6,7-tetrahydro-4H-pyrazolo[4,3-c]pyridin-4-one
  • Step 3 Synthesis of (E)-2-(2-((5-cyclopropyl-4-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-3-fluoroallyl)isoindole-1,3-dione
  • Step 4 Synthesis of (E)-1-(2-(aminomethyl)-3-fluoroallyl)-5-cyclopropyl-1,5,6,7-tetrahydro-4H-pyrazolo[4,3-c]pyridin-4-one hydrochloride
  • the crude product was dissolved in a small amount of ethanol.
  • the solution was added with hydrogen chloride ethanol (0.1 mL) and stirred for 1 h, so that solids were precipitated.
  • MTBE and PE were added, so that white solids were precipitated.
  • the resulting mixture was filtered under vacuum, and the filter cake was dried to give a product (40 mg, yield: 74.9%).
  • Step 1 Synthesis of Intermediate (E)-(3-fluoro-2-((5-ethyl-4-oxo-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)allyl)tert-butyl carbamate
  • Step 2 Synthesis of Compound (E)-2-(2-(aminomethyl)-3-fluoroallyl)-5-ethyl-2,5,6,7-tetrahydro-4H-pyrazolo[4,3-c]pyridin-4-one hydrochloride
  • Step 1 Synthesis of ethyl 3-(tert-butylamino)propionate
  • Step 2 Synthesis of ethyl 3-(tert-butyl(3-ethoxy-3-oxopropyl)amino)-3-oxopropionate
  • the reaction was performed at 85° C. for 5 h, and then at 95° C. for 1.5 h. After the reaction was completed, as detected by LC-MS, the reaction solution was cooled to room temperature, and sodium chloride was added until the reaction solution was saturated. Dichloromethane (400 mL ⁇ 3) was added for extraction. The organic phase was dried and concentrated to give an oily crude product. After cooling, solids were precipitated. Then MTBE was added, and the mixture was stirred, so that a large amount of solids were precipitated. The resulting mixture was filtered under vacuum, and the filter cake was rinsed with a small amount of MTBE and dried to give a product (45.3 g, yield: 67.48%).
  • the intermediate 1-tert-butylpiperidin-2,4-dione (40 g, 0.207 mol, 1.0 eq.) was dissolved in N,N-dimethylformamide dimethyl acetal (35.04 g, 0.265 mol, 1.28 eq.) to react at room temperature for 3 h. After the reaction was completed, as detected by TLC, the reaction solution was concentrated under reduced pressure to give the intermediate (E)-1-tert-butyl-3-((dimethylamino) methylene)piperidin-2,4-dione.
  • the intermediate was added with methanol (200 mL) and hydrazine hydrate (15.3 g, 0.228 mol, 1.1 eq.), and reacted at reflux for 1 h. After the reaction was completed, as detected by LC-MS, the reaction solution was concentrated under reduced pressure, added with MTBE (300 mL), and stirred overnight, and a large amount of solids were precipitated. The resulting mixture was filtered under vacuum, and the filter cake was rinsed with MTBE and dried to give a product (40.00 g, yield: 87.7%).
  • Step 5 Synthesis of (E)-2-(2-((5-tert-butyl-4-oxo-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)-3-fluoroallyl)isoindolin-1,3-dione
  • reaction solution was added with water (12 mL) and extracted with a mixture of dichloromethane and methanol (10:1, 25 mL ⁇ 3), followed by liquid separation. The organic phases were combined, backwashed with water, dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure.
  • Step 6 Synthesis of (E)-2-(2-(aminomethyl)-3-fluoroallyl)-5-tert-butyl-2,5,6,7-tetrahydro-4H-pyrazolo[4,3-c]pyridin-4-one hydrochloride
  • Step 1 Synthesis of ethyl 3-(cyclobutylamino)propionate
  • Step 2 Synthesis of ethyl 3-(cyclobutyl(3-ethoxy-3-oxopropyl)amino)-3-oxopropionate
  • Step 3 Synthesis of ethyl 1-cyclobutyl-2,4-dioxopiperidin-3-carboxylate
  • Step 7 Synthesis of (E)-2-(2-((5-cyclobutyl-4-oxo-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)-3-fluoroallyl)isoindolin-1,3-dione
  • Step 8 Synthesis of (E)-2-(2-(aminomethyl)-3-fluoroallyl)-5-cyclobutyl-2,5,6,7-tetrahydro-4H-pyrazolo[4,3-c]pyridin-4-one hydrochloride
  • Step 2 Synthesis of Intermediate ethyl 3-(cyclopentyl(3-ethoxy-3-oxopropyl) amino)-3-oxopropionate
  • Step 3 Synthesis of Intermediate ethyl 1-cyclopentyl-2,4-dioxopiperidin-3-carboxylate
  • Step 5 Synthesis of Intermediate 1-cyclopentyl-3-((dimethylamino) methylene)piperidin-2,4-dione
  • Step 7 Synthesis of Intermediate (E)-2-(2-((5-cyclopentyl-4-oxo-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)-3-fluoroallyl)isoindolin-1,3-dione
  • Step 8 Synthesis of Compound (E)-2-(2-(aminomethyl)-3-fluoroallyl)-5-cyclopentyl-2,5,6,7-tetrahydro-4H-pyrazolo[4,3-c]pyridin-4-one hydrochloride
  • Step 1 Synthesis of Intermediate ethyl tert-butyl glycinate
  • Step 2 Synthesis of Intermediate ethyl 3-(tert-butyl(2-ethoxy-2-oxoethyl) amino)-3-oxopropionate
  • Ethyl tert-butyl glycinate (6.0 g, 37.68 mmol, 1.0 eq.), monoethyl malonate (5.48 g, 41.15 mmol, 1.1 eq.), triethylamine (8.77 g, 86.67 mmol, 2.3 eq.) and DMAP (921 mg, 7.54 mmol, 0.2 eq.) were successively added to DCM (150 mL), then EDCI (8.62 g, 45.22 mmol, 1.2 eq.) was added to DCM in batches. The mixture was stirred at room temperature overnight.
  • reaction solution was poured into 1 mol/L hydrochloric acid (300 mL), followed by liquid separation.
  • the organic phase was washed successively with water (50 mL) and saturated brine (100 mL), dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated to give a product (10.0 g, yield: 97.1%).
  • Step 3 Synthesis of Intermediate ethyl 1-(tert-butyl)-2,4-dioxopyrrolidin-3-carboxylate
  • Ethyl 1-(tert-butyl)-2,4-dioxopyrrolidin-3-carboxylate (8.31 g, 36.57 mmol, 1.0 eq.) was added to 1 mol/L hydrochloric acid (150 mL) in batches. After addition, the mixture was stirred at 85° C. for 4 h. After the reaction was completed, as detected by TLC, the reaction solution was cooled to room temperature, and added with DCM (200 mL), followed by liquid separation.
  • Step 5 Synthesis of Intermediate 1-(tert-butyl)-3-((dimethylamino) methylene)pyrrolidin-2,4-dione
  • Benzylhydrazine dihydrochloride (2.76 g, 14.17 mmol, 1.0 eq.) and 1-(tert-butyl)-3-((dimethylamino)methylene)pyrrolidin-2,4-dione (2.98 g, 14.17 mmol, 1.0 eq.) were successively added to ethanol (30 mL), and the mixture was stirred at 20° C. for 1 h. Then the mixture was heated to 90° C. to react for 3 h. After the reaction was completed, as detected by TLC, the reaction solution was cooled to room temperature, poured into saturated aqueous sodium bicarbonate solution (50 mL) and extracted with DCM (25 mL ⁇ 3).
  • Step 8 Synthesis of Intermediate (E)-2-(2-((5-(tert-butyl)-4-oxo-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)methyl)-3-fluoroallyl)isoindolin-1,3-dione
  • reaction solution was filtered, and the filter cake was rinsed with ethyl acetate (30 mL).
  • the organic phase was washed with water (20 mL) and saturated brine (20 mL), dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated.
  • Step 9 Synthesis of Compound (E)-2-(2-(aminomethyl)-3-fluoroallyl)-5-(tert-butyl)-5,6-dihydropyrrolo[3,4-c]pyrazol-4(2H)-one
  • Step 1 Synthesis of Intermediate (E)-(3-fluoro-2-((5-(4-fluorophenyl)-4-oxo-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)allyl)tert-butyl carbamate
  • Step 2 Synthesis of Compound (E)-2-(2-(aminomethyl)-3-fluoroallyl)-5-(4-fluorophenyl)-2,5,6,7-tetrahydro-4H-pyrazolo[4,3-c]pyridine hydrochloride
  • Step 1 Synthesis of 5-cyclopropyl-2-(3-fluorophenyl)-1,2,6,7-tetrahydro-3H-pyrazolo[4,3-c]pyridin-3,4(5H)-dione
  • Step 2 Synthesis of (E)-5-cyclopropyl-1-(2-((1,3-dioxoisoindolin-2-yl) methyl)-3-fluoroallyl)-2-(3-fluorophenyl)-1,2,6,7-tetrahydro-3H-pyrazolo[4,3-c]pyridin-3,4(5H)-dione
  • Step 3 Synthesis of (E)-1-(2-(aminomethyl)-3-fluoroallyl)-5-cyclopropyl-2-(3-fluorophenyl)-1,2,6,7-tetrahydro-3H-pyrazolo[4,3-c]pyridin-3,4(5H)-dione
  • Step 1 Synthesis of (E)-1-(2-(aminomethyl)-3-fluoroallyl)-5-(tert-butyl)-1,5,6,7-tetrahydro-4H-pyrazolo[4,3-c]pyridin-4-one
  • Step 1 Synthesis of Intermediate 1-cyclopropyl-3-((dimethylamino) methylene)piperidin-2,4-dione
  • Step 5 Synthesis of Intermediate (Z)-2-(2-((5-cyclopropyl-4-oxo-4,5,6,7-tetrahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)methyl)-3-fluoroallyl)isoindolin-1,3-dione
  • Step 6 Synthesis of Compound (E)-2-(2-(aminomethyl)-3-fluoroallyl)-5-cyclopropyl-2,5,6,7-tetrahydro-4H-pyrrolo[3,4-c]pyridin-4-one
  • Step 1 Synthesis of Intermediate (E)-2-(2-((5-(tert-butyl)-4-oxo-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)-3-fluoroallyl)isoindolin-1,3-dione
  • Step 2 Synthesis of Intermediate (E)-2-(3-fluoro-2-((4-oxo-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)allyl)isoindolin-1,3-dione
  • Step 4 Synthesis of Intermediate (E)-(3-fluoro-2-((4-oxo-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)allyl)tert-butyl carbamate
  • Step 5 Synthesis of Compound (E)-2-(2-(aminomethyl)-3-fluoroallyl)-2,5,6,7-tetrahydro-4H-pyrazolo[4,3-c]pyridin-4-one hydrochloride
  • Step 1 Synthesis of Intermediate (E)-(3-fluoro-2-((5-methyl-4-oxo-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)allyl)tert-butyl carbamate
  • aqueous ethylamine solution (29.1 g, 419.51 mmol, 1.4 eq., 65%) was dissolved in ethanol (100 mL). Then the solution was added with a solution of ethyl acrylate (30.00 g, 299.65 mmol, 1.0 eq.) in ethanol (20 mL) dropwise (1.5 h). After addition, the mixture was stirred at room temperature for 1 h. The reaction solution was concentrated to give a product (42.0 g, yield: 96.5%).
  • Step 2 Synthesis of Intermediate ethyl 3-((3-ethoxy-3-oxopropyl)(ethyl) amino)-3-oxopropionate
  • reaction solution was poured into water (300 mL), and the pH was adjusted to 3-4 with 3 mol/L hydrochloric acid, followed by liquid separation.
  • the organic phase was washed successively with water (150 mL ⁇ 2) and saturated brine (300 mL), dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated to give a product (29.0 g, yield: 81.2%).
  • Step 3 Synthesis of Intermediate ethyl 1-ethyl-2,4-dioxopiperidin-3-carboxylate
  • Ethyl 1-ethyl-2,4-dioxopiperidin-3-carboxylate (23.85 g, 111.84 mmol, 1.0 eq.) was added to 2 mol/L hydrochloric acid (300 mL) in batches. Then the mixture was heated to 100° C. to react for 3 h. After the reaction was completed, as detected by TLC, the reaction solution was cooled to room temperature and extracted with DCM (150 mL ⁇ 3). The organic phase was washed successively with water (100 mL) and saturated brine (100 mL), dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated to give a product (12.0 g, two-step yield: 76.0%).
  • Step 6 Synthesis of Intermediate ((1-ethyl-2,4-dioxopiperidin-3-ylidene) methyl)glycine
  • the intermediate ((1-ethyl-2,4-dioxopiperidin-3-ylidene)methyl)glycine (10.12 g, 42.49 mmol, 1.0 eq.) was added to acetic anhydride (80 mL). Then the mixture was stirred at 120° C. for 5 h. After the reaction was completed, as detected by LC-MS, the reaction solution was concentrated, and the residue was poured into saturated aqueous sodium bicarbonate solution (200 mL). Ethyl acetate (50 mL ⁇ 3) was added for extraction. The organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated to give a crude product (calculated according to theoretical yield), which was directly used in the next step.
  • reaction solution was concentrated, added with ethyl acetate (200 mL), washed successively with water (50 mL) and saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated.
  • the crude product was purified by silica gel column chromatography (ethyl acetate:petroleum ether, 1:1-1:0, v/v) to give a product (2.2 g, four-step yield: 31.53%).
  • Step 9 Synthesis of Intermediate (Z)-2-(2-((5-ethyl-4-oxo-4,5,6,7-tetrahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)methyl)-3-fluoroallyl)isoindolin-1,3-dione
  • the reaction solution was cooled to room temperature and filtered, and the filter cake was rinsed with ethyl acetate (40 mL).
  • the organic phase was washed successively with water (20 mL ⁇ 2) and saturated brine (20 mL), dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated.
  • the crude product was purified by silica gel column chromatography (ethyl acetate) to give a product (1.45 g, yield: 41.6%).
  • Step 10 Synthesis of Compound (E)-2-(2-(aminomethyl)-3-fluoroallyl)-5-ethyl-2,5,6,7-tetrahydro-4H-pyrrolo[3,4-c]pyridin-4-one
  • Step 1 Synthesis of Compound (E)-1-(2-(aminomethyl)-3-fluoroallyl)-5-(tert-butyl)-5,6-dihydropyrrolo[3,4-c]pyrazol-4(11H)-one
  • the reaction solution was cooled to room temperature and filtered, and the filter cake was rinsed with a small amount of ethanol.
  • the filtrate was concentrated, added with absolute ethanol (3.0 mL), and filtered, and the resulting filtrate was concentrated.
  • the crude product was purified by preparative thin-layer chromatography (dichloromethane:methanol, 5:1, v/v) to give a product (35 mg, yield: 52.1%).
  • Step 1 Synthesis of ethyl 3-(isopropylamino)propionate
  • the material isopropylamine (7.09 g, 0.12 mol, 1.2 eq.) was dissolved in ethanol (20 mL). Then the solution was slowly added with ethyl acrylate (10 g, 0.1 mol, 1.0 eq.) dropwise under an ice bath to react for 12 h. After no materials were left, as detected by TLC, the reaction solution was concentrated under reduced pressure to give a product (15 g, yield: 94%).
  • Step 2 Synthesis of ethyl 3-(isopropyl(3-ethoxy-3-oxopropyl)amino)-3-oxopropionate
  • Step 3 Synthesis of ethyl 1-isopropyl-2,4-dioxopiperidin-3-carboxylate
  • Step 7 Synthesis of (E)-2-(2-((5-isopropyl-4-oxo-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)-3-fluoroallyl)isoindolin-1,3-dione
  • Step 8 Synthesis of (E)-2-(2-(aminomethyl)-3-fluoroallyl)-5-isopropyl-2,5,6,7-tetrahydro-4H-pyrazolo[4,3-c]pyridin-4-one hydrochloride
  • the oily liquid was added with methanol (2 mL), followed by hydrogen chloride ethanol solution (0.15 mL), stirred for 5 min, and concentrated under reduced pressure to give a product (60 mg, yield: 39%).
  • Step 2 Synthesis of methyl (E)-1-(2-((1,3-dioxoisoindolin-2-yl)methyl)-3-fluoroallyl)-1H-pyrazole-4-carboxylate
  • Step 3 Synthesis of methyl (E)-1-(2-(aminomethyl)-3-fluoroallyl)-1H-pyrazole-4-carboxylate
  • Step 4 Synthesis of methyl (E)-1-(2-(((tert-butoxycarbonyl)amino) methyl)-3-fluoroallyl)-1H-pyrazole-4-carboxylate
  • Step 5 Synthesis of (E)-1-(2-(((tert-butoxycarbonyl)amino)methyl)-3-fluoroallyl)-1H-pyrazole-4-carboxylic acid
  • Step 6 Synthesis of (E)-(3-fluoro-2-((4-(methylcarbamoyl)-1H-pyrazol-1-yl)methyl)allyl)tert-butyl carbamate
  • Step 1 Synthesis of tert-butyl (E)-(2-((4-(ethylcarbamoyl)-1H-pyrazol-1-yl)methyl)-3-fluoroallyl)carbamate
  • reaction solution was added with EA (70 mL) and aqueous sodium carbonate solution (40 mL), followed by liquid separation.
  • the organic phase was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure.
  • Step 1 Synthesis of tert-butyl (E)-(2-((4-(tert-butylcarbamoyl)-1H-pyrazol-1-yl)methyl)-3-fluoroallyl)carbamate
  • reaction solution was concentrated under reduced pressure, and added with EA (100 mL) and aqueous sodium carbonate solution (60 mL), followed by liquid separation.
  • the organic phase was dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated under reduced pressure.
  • Step 1 Synthesis of tert-butyl (E)-(2-((4-(cyclopropylcarbamoyl)-1H-pyrazol-1-yl)methyl)-3-fluoroallyl)carbamate
  • reaction solution was concentrated under reduced pressure and added with EA (50 mL), saturated aqueous ammonium chloride solution (30 mL) and saturated aqueous sodium chloride solution (30 mL), and liquid separation was performed.
  • the organic phase was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure.
  • the crude product was purified by silica gel column chromatography to give the product (97.6 mg, yield: 65.5%).
  • Step 1 Synthesis of methyl (Z)-1-(2-((1,3-dioxoisoindolin-2-yl)methyl)-3-fluoroallyl)-1H-pyrrole-3-carboxylate
  • Step 2 Synthesis of methyl (E)-1-(2-aminomethyl-3-fluoroallyl)-1H-pyrrole-3-carboxylate
  • Step 3 Synthesis of methyl (E)-1-(2-(((tert-butoxycarbonyl)amino) methyl-3-fluoroallyl)-1H-pyrrole-3-carboxylate
  • Step 4 Synthesis of (E)-1-(2-(((tert-butoxycarbonyl)amino)methyl)-3-fluoroallyl)-1H-pyrrole-3-carboxylic acid
  • Step 5 Synthesis of tert-butyl (E)-(2-((3-(ethylcarbamoyl)-1H-pyrrol-1-yl)methyl)-3-fluoroallyl)carbamate
  • the reaction solution was concentrated under reduced pressure.
  • the concentrate was dissolved in EA (60 mL), and saturated aqueous NaHCO 3 solution (50 mL), saturated aqueous NH 4 Cl solution (50 mL) and saturated brine (50 mL ⁇ 4) were sequentially used for washing.
  • the organic phase was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure.
  • Step 1 Synthesis of tert-butyl (E)-(2-((3-(tert-butylcarbamoyl)-1H-pyrrol-1-yl)methyl)-3-fluoroallyl)carbamate
  • the reaction solution was concentrated under reduced pressure.
  • the concentrate was dissolved in EA (60 mL), and saturated aqueous NaHCO 3 solution (50 mL), saturated aqueous NH 4 Cl solution (50 mL) and saturated brine (50 mL ⁇ 4) were sequentially used for washing.
  • the organic phase was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure.
  • Step 1 Synthesis of tert-butyl (E)-(2-((3-(ethylcarbamoyl)-1H-pyrazol-1-yl)methyl)-3-fluoroallyl)carbamate
  • reaction solution was added with EA (40 mL) and saturated aqueous sodium carbonate solution (50 mL), followed by liquid separation.
  • the organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure.
  • Step 1 Synthesis of methyl (E)-1-(2-((1,3-dioxoisoindolin-2-yl)methyl)-3-fluoroallyl)-1H-pyrazole-3-carboxylate
  • Step 2 Synthesis of methyl (E)-1-(2-(aminomethyl)-3-fluoroallyl)-1H-pyrazole-3-carboxylate
  • Step 3 Synthesis of methyl (E)-1-(2-(((tert-butoxycarbony)amino) methyl)-3-fluoroallyl)-1H-pyrazole-3-carboxylate
  • Step 4 Synthesis of (E)-1-(2-(((tert-butoxycarbony)amino)methyl)-3-fluoroallyl)-1H-pyrazole-3-carboxylic acid
  • Step 5 Synthesis of tert-butyl (E)-(2-((3-(tert-butylcarbamoyl)-1H-pyrazol-1-yl)methyl)-3-fluoroallyl)carbamate
  • reaction solution was concentrated under reduced pressure and added with EA (60 mL) and saturated aqueous sodium carbonate solution (50 mL), followed by liquid separation.
  • the organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure.
  • Step 1 Synthesis of tert-butyl (E)-(2-((4-((4-chlorophenyl)carbamoyl)-1H-pyrazol-1-yl)methyl)-3-fluoroallyl)carbamate
  • the reaction solution was concentrated under reduced pressure.
  • the concentrate was dissolved in EA (60 mL), and saturated aqueous NaHCO 3 solution (50 mL), saturated aqueous NH 4 Cl solution (50 mL) and saturated brine (50 mL ⁇ 4) were sequentially used for washing.
  • the organic phase was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure.
  • Step 1 Synthesis of tert-butyl (E)-(2-((4-(dimethylcarbamoyl)-1H-pyrazol-1-yl)methyl)-3-fluoroallyl)carbamate
  • Step 1 Synthesis of methyl (E)-1-(2-(aminomethyl)-3-fluoroallyl)-1H-pyrazole-5-carboxylate
  • Step 2 Synthesis of methyl (E)-1-(2-(((tert-butoxycarbony)amino) methyl)-3-fluoroallyl)-1H-pyrazole-5-carboxylate
  • Step 3 Synthesis of (E)-1-(2-(((tert-butoxycarbony)amino)methyl)-3-fluoroallyl)-1H-pyrazole-5-carboxylic acid
  • Step 4 Synthesis of tert-butyl (E)-(2-((5-(tert-butylcarbamoyl)-1H-pyrazol-1-yl)methyl)-3-fluoroallyl)carbamate
US17/421,428 2019-01-11 2020-01-10 Haloallylamine compounds and application thereof Pending US20220081439A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN201910025251.8 2019-01-11
CN201910025251 2019-01-11
CN201910196383.7 2019-03-15
CN201910196383 2019-03-15
CN201910434159.7 2019-05-23
CN201910434159 2019-05-23
CN201910914387 2019-09-24
CN201910914387.4 2019-09-24
CN201911026383 2019-10-26
CN201911026383.9 2019-10-26
PCT/CN2020/071405 WO2020143763A1 (zh) 2019-01-11 2020-01-10 卤代烯丙基胺类化合物及其应用

Publications (1)

Publication Number Publication Date
US20220081439A1 true US20220081439A1 (en) 2022-03-17

Family

ID=71521993

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/421,428 Pending US20220081439A1 (en) 2019-01-11 2020-01-10 Haloallylamine compounds and application thereof

Country Status (20)

Country Link
US (1) US20220081439A1 (zh)
EP (1) EP3892621A4 (zh)
JP (1) JP2022517085A (zh)
KR (1) KR20210113287A (zh)
CN (1) CN111434662B (zh)
AU (1) AU2020206477B2 (zh)
BR (1) BR112021013429A2 (zh)
CA (1) CA3122623C (zh)
CL (1) CL2021001629A1 (zh)
CO (1) CO2021010493A2 (zh)
IL (1) IL284514A (zh)
JO (1) JOP20210185A1 (zh)
MX (1) MX2021006724A (zh)
PE (1) PE20212155A1 (zh)
PH (1) PH12021551232A1 (zh)
SG (1) SG11202107498VA (zh)
TW (1) TWI783205B (zh)
UA (1) UA126997C2 (zh)
WO (1) WO2020143763A1 (zh)
ZA (1) ZA202105752B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
BR112021010341A2 (pt) 2018-12-14 2021-08-24 Yuhan Corporation 3,3-difluoroalilaminas ou sais das mesmas e composições farmacêuticas que compreendem as mesmas
CN117230091B (zh) * 2023-11-16 2024-01-19 四川大学华西第二医院 一种亚胺还原酶ir11或其突变体及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
ES2668300T3 (es) * 2012-05-02 2018-05-17 Boehringer Ingelheim International Gmbh Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos
WO2018027892A1 (en) * 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) * 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
US20200087248A1 (en) * 2017-04-28 2020-03-19 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Fluoroallylamine Derivative And Use Thereof
CN109810041B (zh) * 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109988106B (zh) * 2017-12-29 2023-03-31 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN109988109B (zh) * 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
WO2020006177A1 (en) * 2018-06-29 2020-01-02 Blade Therapeutics, Inc. Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof

Also Published As

Publication number Publication date
PE20212155A1 (es) 2021-11-09
EP3892621A1 (en) 2021-10-13
CA3122623C (en) 2024-02-13
JP2022517085A (ja) 2022-03-04
CA3122623A1 (en) 2020-07-16
WO2020143763A1 (zh) 2020-07-16
MX2021006724A (es) 2021-11-04
JOP20210185A1 (ar) 2023-01-30
KR20210113287A (ko) 2021-09-15
CO2021010493A2 (es) 2021-10-29
TWI783205B (zh) 2022-11-11
CN111434662A (zh) 2020-07-21
CN111434662B (zh) 2023-01-10
TW202039491A (zh) 2020-11-01
AU2020206477A1 (en) 2021-06-17
AU2020206477B2 (en) 2022-11-10
ZA202105752B (en) 2022-12-21
BR112021013429A2 (pt) 2021-10-19
CL2021001629A1 (es) 2021-12-17
SG11202107498VA (en) 2021-08-30
IL284514A (en) 2021-08-31
EP3892621A4 (en) 2022-02-09
UA126997C2 (uk) 2023-03-01
PH12021551232A1 (en) 2021-11-08

Similar Documents

Publication Publication Date Title
US10858359B2 (en) Heterocyclic ring derivatives useful as SHP2 inhibitors
US20220081439A1 (en) Haloallylamine compounds and application thereof
US8664219B2 (en) Aminopyrimidines useful as inhibitors of protein kinases
EP2086965B1 (en) Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
US20080113967A1 (en) Enzyme modulators and treatments
US20070135466A1 (en) Pyrrolopyridines useful as inhibitors of protein kinase
US20120316186A1 (en) Deazapurines useful as inhibitors of janus kinases
US20110021559A1 (en) Aminopyridines useful as inhibitors of protein kinases
WO2008112651A2 (en) Aminopyrimidines useful as inhibitors of protein kinases
US9926318B2 (en) Tetracyclic autotaxin inhibitors
CN111410659B (zh) Pde9抑制剂及其用途
US20190263828A1 (en) Heteroaromatic compounds as vanin inhibitors
WO2020150545A1 (en) Pyrazole derivatives as modulators of the wnt/b-catenin signaling pathway
US20230150980A1 (en) Collagen 1 translation inhibitors and methods of use thereof
US20220370431A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
RU2793850C2 (ru) Производные галогеналлиламина и их применение
MX2008001172A (en) Benzimidazoles useful as inhibitors of protein kinases

Legal Events

Date Code Title Description
AS Assignment

Owner name: TRANSTHERA SCIENCES (NANJING), INC., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WAN, ZHONGHUI;LI, LIN;WU, FRANK;SIGNING DATES FROM 20180102 TO 20210730;REEL/FRAME:057782/0350

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION